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Summary
Vasodilation to histamine in the isolated perfused rat 
kidney: roles of nitric oxide (NO), cyclo-oxygenase 
products and H3 , H2 and H3 receptors
The roles of nitric oxide (NO) and cyclo-oxygenase 
products as possible mediators of vasodilation to 
histamine in the preconstricted isolated perfused rat 
kidney have been assessed. Histamine (l-300nmoles) 
elicited dose-dependent reductions in renal perfusion 
pressure in preparations preconstricted to the same level 
with either potassium (30mM) or the a^-adrenoceptor 
agonist, methoxamine (3/xM) . However, renal vasodilation 
to histamine (l-300nmoles) was smaller in preparations 
preconstricted with potassium (30mM). The selective NO 
synthase inhibitors, NG-nitro-L-arginine methyl ester (L- 
NAME, 0.3mM) and NG-nitro-L-arginine (L-NOARG, 0.3mM), 
did not affect renal vasodilation to histamine in 
preparations preconstricted with either potassium (30mM) 
or methoxamine (3jiiM) . Furthermore, the cyclo-oxygenase 
inhibitor, indomethacin (10/zM), did not affect renal 
vasodilation to histamine in potassium(3OmM)- 
preconstricted preparations. The H2 receptor antagonist 
ranitidine (0.1-10/iM) reduced and finally abolished renal 
vasodilation to histamine (30nmoles) in a concentration- 
dependent manner with a pA2 of 6.67, estimated from a
Vfunctional inhibition curve. These results provide 
evidence that neither NO nor cyclo-oxygenase products 
play a role in a predominantly H2 receptor-mediated 
vasodilation to histamine in the preconstricted isolated 
perfused rat kidney.
Vasoconstriction to endothelins in the isolated perfused
rat kidney: effects of BQ123 and indomethacin
Endothelin-1 (ET-1), ET-2 and ET-3 (l-100pmoles) acted as 
equipotent vasoconstrictors in the isolated perfused rat 
kidney. Vasoconstriction to ETs was transient. The time 
to 75% recovery from the peak rise in perfusion pressure 
was similar for ET-1 and ET-2 (30pmoles) while that for 
ET-3 (30pmoles) was relatively shorter. The selective ET^ 
receptor antagonist BQ123 (1/xM) , reduced peak 
vasoconstrictor responses only to lower doses of ET-1 
(3,10 pmoles) . However, the time to 75% recovery from the 
peak rise in perfusion pressure to a higher dose of ET-1 
(30pmoles) was reduced in the presence of BQ123 (1/xM) . 
Vasoconstriction to ET-3 (3-30pmoles) was unaffected by 
BQ123 (1/xM) . In addition, cylco-oxygenase inhibition with 
indomethacin (10/liM) did not modulate vasoconstriction to 
ET-1 or ET-3 (3-30pmoles). Taken together, the evidence 
suggests that the ET receptors subserving 
vasoconstriction in the rat renal vascular bed include a 
population of both non-ET^ and ET^ sites. Furthermore, it 
is reported that cyclo-oxygenase products do not modulate 
rat renal vasoconstriction to ETs.
Vasoconstrictor reactivity in the isolated perfused rat
kidney after renal ischaemia/reperfusion in vivo
Renal vascular resistance was unaltered in the isolated 
perfused rat kidney following 30min renal ischaemia with 
or without 15min reperfusion in vivo. Vasoconstrictor 
responses to noradrenaline (l-300nmoles) tended to be 
depressed during an intial dose-response series after 
30min ischaemia in vivo. When a second dose-response 
series to noradrenaline (l-300nmoles) was repeated lh 
later, the potency of noradrenaline was observed to have 
increased. No such time-dependent shift in the potency of 
noradrenaline occurred over a similar perfusion period in 
the isolated perfused rat kidney following 30min renal 
ischaemia and 15min reperfusion in vivo. In addition, 
renal vasoconstriction to 5-hydroxytryptamine (1- 
lOOnmoles), ET-1 (3-30pmoles), ET-3 (3-30pmoles) and KC1 
(HOmM) was unaffected following 30min renal ischaemia in 
vivo. Taken together, the results suggest that 30min 
renal ischaemia in vivo is not associated with gross 
changes in vasoconstrictor reactivity or basal vascular 
tone in vitro. However, this period of occlusive renal 
ischaemia appears sufficient to cause a slight, 
reversible depression in vasoconstrictor reactivity to at 
least noradrenaline.
viii
Assessment of myeloperoxidase (MPO) activity in rat renal 
tissue after ischaemia/reperfusion in vivo: effects of 
antibodies against adhesion molecules used by 
polymorphonucleocytes (PMNs)
It has been shown that a photometric assay of MPO derived 
from rat blood PMNs employing 3,31,5,5 * -
tetramethylbenzidine (TMB) as substrate is more sensitive 
than an established assay employing o-dianisidine. It was 
further demonstrated that rat renal tissue is capable of 
inhibiting peroxidase activity. This activity approached 
100% when the rat renal supernate was incubated at 60°C 
for 2h and the assay was conducted in the presence of a 
1 0-fold higher concentration of hydrogen peroxide (H2O2 ). 
Rat kidneys undergoing 45min ischaemia and 1, 3 and 6h 
reperfusion in vivo, exhibited significant increases in 
MPO activity, indicating PMN accumulation. Monoclonal 
antibodies (MoAbs) against rat intercellular adhesion 
molecule 1 (ICAM-1) and CD18 of B2~integrins administered 
both 5min before a period of 45min renal ischaemia 
(20/zg/kg via tail vein) and at the commencement of lh 
reperfusion (20/xg/kg via tail vein) reduced renal PMN 
accumulation. However, similar treatment with the 
isotype-matched control murine antibody IgG^ and an 
unrelated murine antibody, IgG2a, also significantly 
reduced renal PMN accumulation. In conclusion, it can be 
demonstrated that the rat renal suppression of peroxidase 
activity may be overcome by a combination of heat
inactivation and the provision of excess assay H2O2 . In 
addition, the available evidence suggests that murine 
MoAbs against rat adhesion molecules may exert non­
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1.1. The renal circulation
The renal artery enters the mammalian kidney at the hilum 
and divides into ventral and dorsal branches (Figure 1). 
These branches develop into interlobar arteries which 
ascend through the renal columns of the medulla to supply 
the arcuate arteries at the corticomedullary junction. 
Arcuate arteries then feed interlobular arteries which 
ascend through the cortex and engender afferent 
arterioles. Each afferent arteriole gives off lobules 
with associated capillary loops to form glomeruli. Blood 
drains from each glomerulus into an efferent arteriole 
and then into a capillary network. Superficial cortical 
efferent arterioles divide to produce a peritubular 
capillary system which supplies the capsule as well as 
the cortex and eventually drains into stellate and 
interlobular veins. Corticomedullary efferent arterioles 
enter the medulla and subsequently divide to provide vasa 
recta. The arterial vasa recta descend in bundles to 
terminate in capillary plexi either in the outer or inner 
medulla. Blood from the descending vasa recta drains into 
the ascending vasa recta and then into the arcuate and 
interlobar veins which finally converge at the hilum as 
the renal vein. The renal circulation of the kidney is 
therefore atypical in that it possesses two sets of
2Figure 1. Schematic diagram showing A) gross and 
vasculature of the mammalian kidney
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3capsular vessels
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B) efferent arteriole interlobular 










4arterioles and two capillary beds. The cortex is highly 
vascularised and receives approximately 90-95% of total 
renal blood flow which itself represents approximately 
10% of cardiac output (for reviews, see Vander, 1975; 
Brenner et al., 1976; Guyton, 1981; de Wardener, 1985; 
Ross et al., 1989).
A notable feature of the kidney is its autoregulatory 
capacity (see Vander, 1971; de Wardener, 1985). For 
example, renal blood flow is regulated in response to 
changes in arterial pressure by an intrinsic myogenic 
mechanism that influences the resistance of the afferent 
arteriole. This process in concert with another intrinsic 
mechanism, tubuloglomerular feedback which modulates the 
resistance of the efferent arteriole, regulates 
glomerular filtration rate. In addition, there is 
autoregulation of renal plasma flow in response to 
changes in haematocrit. The afferent and efferent 
arterioles in fact provide the major variable resistance 
vessels of the renal microvasculature in the rat (Brenner 
et al., 1971).
1.2. Renal ischaemia
Renal ischaemia may result from a number of diverse 
clinical and traumatic causes (see Schrier, 1980; Klahr, 
1983; Macleod, 1984; de Wardener, 1985). For example,
5cardiac failure or a sustained reduction in blood volume 
may lead to severe renal vasoconstriction which decreases 
renal blood flow. Renal vasoconstriction also occurs in 
response to certain poisons such as carbon tetrachloride, 
mercuric chloride, propylene glycol and may result from 
cyclosporine therapy (de Wardener, 1985). Stenotic 
changes in the renal microvasculature such as those 
arising from: arteriolar nephrosclerosis associated with 
malignant hypertension and systemic scleroderma; 
glomerular endotheliosis associated with eclampsia; the 
renal vascular deposition of glycoprotein in amyloidosis; 
and lesions accompanying renal vascular inflammation in 
periarteritis nodosa and glomerulonephritis, may all lead 
to occlusive renal ischaemia (Black, 1963; Klahr, 1983; 
Schrier, 1980). In renal transplantation, donor kidneys 
are subjected to both warm ischaemia during excision and 
anastomosis and cold ischaemia during storage (see Flynn, 
1974). A restoration of blood flow after ischaemia may 
lead to clinically relevant reperfusion injury (see 
Hearse & Bolli, 1992; Fox, 1992). The
polymorphonucleocyte (PMN) is potentially an important 
component of such injury, as in the microvascular and 
tubular dysfunction seen after renal
ischaemia/reperfusion in the rat (Klausner et al., 1989; 
Hellberg et al., 1988).
61.3. Renal vascular reactivity after 
ischaemia/reperfusion
Normal or defective autoregulation (paradoxical renal 
vasoconstriction in response to reductions in renal 
perfusion pressure), depressed or enhanced 
vasoconstriction to renal nerve stimulation, depressed or 
absent vasoconstriction to noradrenaline and angiotensin 
II and depressed endothelium-dependent vasodilation to 
acetylcholine and depressed or normal vasodilation to 
prostacyclin have all been reported in the rat kidney 
following ischaemia/reperfusion in vivo, depending on the 
model and severity of ischaemia (Conger et al., 1983; 
1988; 1991; Kelleher et al., 1984; Clozel et al., 1991; 
Matthys et al., 1983).
A raised renal vascular resistance is a common finding 
following occlusive ischaemia/reperfusion in the rat in 
vivo (Arendshorst et al., 1975; Paller et al., 1984; 
Clozel et al., 1991; Cristol et al., 1993a). Lieberthal 
et al. (1989) have reproduced this finding in the 
isolated perfused rat kidney following global non­
perfusion and reperfusion with erythrocyte-rich salt 
solution. In their experiments, the enhanced renal 
vascular resistance in vitro was abolished by sodium 
nitroprusside and atrial natriuretic peptide, suggesting 
that vascular tone was elevated in ischaemic kidneys. The 
presumed inhibitors of endothelium-derived relaxing
7factor (EDRF), gossypol and methylene blue (Martin et 
al., 1985), were found to raise renal vascular resistance 
to the same extent as global non-perfusion in 
normoperfused kidneys, suggesting the loss of a basal 
endothelial vasodilator role after ischaemia (Lieberthal 
et al., 1989), Interestingly, Cristol et al. (1993a) have 
suggested that vasodilator prostaglandins such as 
prostacyclin, help to maintain renal blood flow after 
ischaemia while NO release is important in the gradual 
recovery of renal blood flow during reperfusion in vivo. 
Spielman & Osswald (1978) have also defined a role for 
vasodilator prostaglandins in an attenuation of 
postocclusive vasoconstriction in the
ischaemic/reperfused feline kidney in vivo. Furthermore, 
a role for the renal vasoconstrictors, adenosine (Sakai 
et al., 1980) and angiotensin II, in elevated 
postocclusive renal vascular resistance was proposed 
(Spielman & Osswald, 1978; 1979).
A similar scenario of vascular dysfunction is evident in 
the ischaemic myocardium. Ischaemia/reperfusion of canine 
coronary arteries in vivo results in the loss of 
endothelium-dependent vasodilation and enhanced 
contractile activity in subsequently isolated 
preparations in vitro (VanBenthuysen et al., 1987; Ku, 
1982; Sobey et al., 1992); while ischaemia/reperfusion of 
canine myocardium leads to an increase in coronary 
vascular resistance and depressed vasodilator responses
8to both adenosine and papaverine, indicating a deficiency 
in coronary vasodilator reserve (Bolli et al., 1990). In 
addition, reactive hyperaemia after a brief ischaemic 
insult is reduced (Bolli et al., 1990; Laxson et al., 
1989).
1.4. V as coconstrictor reactivity in the isolated perfused 
rat kidney after ischaemia/reperfusion in vivo
Attention has been focussed on the possible role of 
endothelins in the renal vasoconstriction accompanying 
ischaemic acute renal failure in the rat (Conger et al., 
1983; Shibouta et al., 1990). Evidence supporting such a 
role is provided by the findings that the affinity of rat 
renal endothelin binding sites is enhanced (Nambi et al.,
1992) and that the rat renal content of ET-1 is increased 
following ischaemia (Firth & Ratcliffe, 1992; Shibouta et 
al., 1990; Mino et al., 1992). An effect of ischaemia and 
reoxygenation to upregulate endothelin binding sites has 
also been reported by Liu et al. (1990) in the isolated 
rat heart. In addition, antibodies against ET-1 reverse 
postocclusive renal vasoconstriction in rats (Kon et al., 
1989; Lopez-Farre et al., 1991). Endothelins are 
multifunctional renal peptides (see Simonson, 1993) with 
effects on renin release (Matsumara et al., 1988), sodium 
excretion (Ferrario et al., 1989; Yamada & Yoshida, 1991) 
and the glomerular filtration coefficient (Badr et al.,
91989), as well as glomerular filtration rate and renal 
vascular resistance (see Badr et al., 1989; Ferrario et 
al., 1989; Lopez-Farre et al., 1989; Katoh et al., 1990; 
Cairns et al., 1989; Takabatake et al., 1991; Gulbins et 
al., 1993). Accordingly, antibodies against ET-1 and ET-2 
or the selective ET^ receptor antagonist BQ123, have also 
been shown to restore renal function and to prevent 
histological damage in rat models of ischaemic acute 
renal failure (Shibouta et al., 1990; Mino et al., 1992).
It was therefore of interest to determine how vascular 
reactivity to ET-1 and ET-3 together with a number of 
other selected vasoconstrictors in the isolated perfused 
rat kidney, might be affected by previous renal ischaemia 
in vivo.
1.5. Vasoconstriction to endothelins in the isolated 
perfused rat kidney: effects of BQ123 and indomethacin
Endothelins (ETs) and sarafotoxins (SXs) belong to a 
superfamily of conserved 21 amino acid isopeptides. 
Endothelins are found in mammalian tissues (see Simonson 
& Dunn, 1990) while sarafotoxins are constituents of the 
venom of the Israeli burrowing asp (Kloog et al., 1988). 
The first endothelin to be isolated, ET-1 from porcine 
endothelial cells, acts as a potent constrictor of smooth 
muscle in a variety of preparations (Yanagisawa et al.,
10
1988; D'Orleans-Juste et al., 1988; MacLean & McGrath,
1990) . However, ET-1 may also be demonstrated to exert 
vasodilator effects in vitro in the isolated perfused rat 
heart (Baydoun et al., 1989) and isolated perfused rat 
mesentery (de Nucci et al., 1988; Warner et al., 1989) 
and in vivo in the rat hindlimb (Ohlstein et al., 1990), 
rat systemic vascular bed (Wright & Fozard, 1988; de 
Gouville et al., 1990) and feline systemic vascular bed 
(Lippton et al., 1988).
Endothelin isopeptides are produced by the proteolytic 
cleavage of 38- to 39-amino acid precursors, big 
endothelins, by a phosphoramidon-sensitive neutral 
endopeptidase known as endothelin converting enzyme 
(Masaki et al., 1991; Opgenorth et al., 1992; Simonson, 
1993). It has been demonstrated in the anaesthetised rat 
that exogenous big ET-1 exerts additional renal effects 
to exogenous ET-1 (Pollock & Opgenorth, 1994). This 
finding could represent the local conversion of exogenous 
big ET-1 at specific sites not accessible to exogenous 
ET-1. The release of ET-1 from a variety of vascular and 
non-vascular cells is stimulated by a number of factors 
including shear stress, hypoxia, thrombin, thromboxane 
A2 , bradykinin and IL-1 (see Simonson, 1993).
Two ET/SX receptors have been characterised to date: ET^ 
with a rank order of binding affinities ET-1>ET- 
2>SX6b>ET-3 (Arai et al., 1990); and ET3 which is
11
isopeptide non-selective (Sakurai et al,, 1990). There is 
some evidence for additional ET/SX receptor sites (Emori 
et al., 1990; Harrison et al., 1992; Martin et al., 1990; 
Samson et al., 1990; Watanabe et al., 1989).
Endothelins activate phospholipase C leading to the 
hydrolysis of phosphatidyl-4,5-bisphosphate and the 
formation of inositol 1 ,4,5-trisphosphate (IP3 ) and 1 ,2- 
diacylglycerol (DAG) (Resink et al., 1988; Kasuya et al., 
1989; Cioffi et al., 1991) with a concomitant activation 
of protein kinase C (PKC) (Lee et al., 1989). ET-1 also 
closes benzopyran-sensitive potassium channels (Lawson et 
al., 1992). Hence, smooth muscle constriction to 
endothelins may occur via several mechanisms, including 
internal calcium release, trans-sarcolemmal calcium 
influx through voltage-operated (Godfraind et al., 1989; 
Goto et al., 1989) and receptor-operated channels 
(Ninomiya et al., 1992; Suzuki et al., 1992), an 
inhibition of calcium extrusion (Wallnoeffer et al.,
1989) and a sensitisation of contractile elements to 
calcium (for review, see Highsmith et al., 1992). An 
effect of ET-1 to activate voltage-operated channels 
(Goto et al., 1989) appears not to be due to a 
dihydropyridine agonist-like activity (Nakayama et al.,
1991) and is conceivably mediated intracellularly by a 
second messenger such as PKC (see Vivaudou et al., 1988; 
Rasmussen et al., 1987).
12
In addition, endothelins activate phospholipase A2 
(Resink et al., 1989) leading to a cascade of vasoactive 
arachidonate metabolites in various preparations 
(thromboxane A2 (de Nucci et al., 1988); prostaglandin E2 
(PGE2) (Rae et al., 1989); prostacyclin (Lidbury et al., 
1990; de Nucci et al., 1988); lipoxygenase products 
(Nagase et al., 1990)). Furthermore, endothelins have 
been shown to release platelet activating factor (PAF) 
(Ninomiya et al., 1992; Terashita et al., 1989), 
angiotensin II (Kawaguchi et al., 1990), atrial 
natriuretic peptide (ANP) (Hu et al., 1988), NO (de Nucci 
et al., 1988; Warner et al., 1989) and histamine 
(Ninomiya et al., 1992) in a host of preparations.
Evidence has emerged that the ET^ receptor is not an 
exclusive mediator of smooth muscle contraction to 
endothelins. Warner et al. (1992) have found in vitro 
that the selective ET^ receptor antagonist BQ123 (Ihara 
et al., 1992a; Nakamichi et al., 1992) fails to modulate 
the constrictor effect of ET-1 in the guinea-pig 
bronchus, rat stomach strip and rabbit pulmonary artery, 
but in contrast does produce blockade in the rat thoracic 
aorta. More recently, Cardell et al. (1993) have shown 
that the ET-l-induced contraction of the isolated guinea- 
pig trachea is insensitive to the novel selective ET^ 
receptor antagonist, FR13917. In vivo, Bigaud & Pelton 
(1992), Cristol et al. (1993b) and McMurdo et al. (1993) 
have shown that BQ123 largely depresses but does not
13
abolish the pressor effects of endothelins in the 
anaesthetised rat. In addition, Douglas et al. (1992) 
have not been able to abolish the ET^-mediated secondary 
pressor effect of ET-1 (Bigaud & Pelton, 1992) using 
BQ123, without compromising the ETg-mediated initial 
depressor effect (Bigaud & Pelton, 1992) in the 
anaesthetised rat.
Direct evidence that the ETg receptor can subserve 
vasconstriction to endothelins/sarafotoxins was provided 
in vivo by the pressor effects of the reputed ET3 - 
selective agonists SX6c (Williams et al., 1991) and 
[Ala1 '3 '1 1 '1 5 ]ET-1 (BQ3020) (Ihara et al., 1992b; Saeki 
et al., 1991) in the anaesthetised (Bigaud & Pelton,
1992; Cristol et al., 1993b; Clozel et al., 1990) and 
pithed rat (Williams et al., 1991). Moreover, in vitro, 
Ihara et al. (1992b) have demonstrated constriction of 
the isolated, endothelium-denuded rabbit pulmonary artery 
to the ETg selective agonist BQ3020. BQ3020 displayed a 
similar potency to both ET-1 and ET-3 as a constrictor 
and responses were unaffected by BQ123. There is also 
evidence linking the ET3 receptor to constriction in the 
porcine coronary artery (Ihara et al., 1992a), where ET^ 
receptors are also present. These findings clearly refute 
the notion that the ETg receptor is dedicated to dilation 
in the vasculature (Takayanagi et al., 1991). In 
contrast, ET-l-elicited contractions of the isolated dog 
(Douglas et al., 1993) and guinea-pig (Cardell et al.,
14
1993) pulmonary artery have indeed been shown to be 
mediated predominantly by ET^ receptors.
Very recent evidence from several in vivo studies in the 
rat indicates that renal vasoconstriction to ETs and SXs 
is mediated by ET^ and non-ET^, ETg-like ET/SX receptors. 
Both Cristol et al. (1993b) and Bigaud and Pelton (1992) 
have shown only partial inhibition of renal 
vasoconstriction to endothelins in the anaesthetised rat 
with the selective ET^ receptor antagonist BQ123. Indeed, 
Pollock & Opgennorth (1993) have reported that ET-1 
elicited renal vasconstriction is unaffected by BQ123 in 
the anaesthetised rat. In direct support of a role for 
ET3 receptors in the renal vasoconstriction to ETs/SXs in 
the anaesthetised rat, Bigaud & Pelton (1992), Clozel et 
al. (1993) and Cristol et al. (1993b) have demonstrated 
increases in renal vascular resistance to the reputed 
ETs-selective agonists, SX6c and BQ3020. Williams et al.
(1991) have also shown renal vasoconstriction to SX6c in 
the pithed rat. Interestingly, the blood pressure- 
elevating effect, but not the renal vasoconstrictor 
effect, of SX6c was found to be partially diminished by 
BQ123 in the anaesthetised rat by Cristol et al. (1993b). 
This raises the possibility that reputed ET3 -selective 
agonists may exert additional effects. Furthermore, a 
non-ET^, non-ET3 , SX6c/ET-3-selective receptor, 
originally described in the porcine coronary artery and 
coupled to constriction (Harrison et al., 1992), may
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conceivably mediate some of the direct effects of SX6c. 
Consistent with an ETg profile, Cristol et al. (1993b) 
determined the rank order of potency of endothelins and 
sarafotoxins as renal vasoconstrictors to be ET-1=ET- 
3=Sx6b=SX6c in the anaesthetised rat. Inconsistent with 
this ETg profile, however, is the failure of the 
nonselective ET3 receptor antagonist PD142893 (Hingorani 
et al., 1992) to inhibit renal vosoconstriction to ET-1 
in the anaesthetised rat (La Douceur et al., 1992). In 
the same preparation, PD142893 was reported to 
selectively inhibit the initial depressor response to ET- 
1 and to inhibit regional vasodilation in the hindlimb.
Such findings in the rat in vivo arguing for a mixed 
population of ET^ and possibly ET3 receptors in renal 
vasoconstriction to endothelins are in contrast to 
studies in other species. For example, the selective ET^ 
receptor antagonists BQ153 (Fukuroda et al., 1992) and 
BQ123 (Ihara et al., 1992a; Nakamichi et al., 1992) have 
been found to substantially reduce vasoconstriction to 
ET-1 in the porcine kidney in situ (Cirino et al., 1992) 
and the isolated perfused rabbit kidney (Telemaque et 
al., 1993), respectively. In addition, the relative 
potency of endothelin isopeptides as vasoconstrictors in 
the isolated perfused rabbit kidney was ET-l>ET-2>ET-3 
while the ETg agonists BQ3020 and IRL1620 were without 
effect (Telemaque et al., 1992; 1993).
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In the present study, the receptors subserving 
vasoconstriction to endothelins in rat isolated perfused 
rat kidney were investigated by establishing a rank order 
of potency for endothelin isopeptides and by examining 
the sensitivity of vasoconstriction induced by ET-1 and 
ET—3 to BQ123 (cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp]), a 
potent and selective cyclic pentapeptide ET^ receptor 
antagonist (Ihara et al., 1992a; Nakamichi et al., 1992). 
In view of the fact that endothelins could conceivably 
modulate their direct vasoconstrictor effects indirectly 
via the release of vasoactive eicosanoids, a role for 
cyclo-oxygenase in the renal vascular reactivity to ET-1 
and ET-3 was additionally examined using indomethacin.
1.6. Vasodilation to histamine in the isolated perfused 
rat kidney as an assessment of EDRF(NO) release?
Histamine acts as a renal vasodilator in the 
preconstricted rat isolated perfused kidney (Bhardwaj & 
Moore, 1988). On the basis of experiments with 
metyrapone, nordihydroguaiaretic acid and gossypol, 
postulated inhibitors of EDRF synthesis, methylene blue, 
a presumed antagonist of the effect of EDRF, and CHAPS, a 
detergent that removes endothelial cells lining blood 
vessels, Bhardwaj & Moore (1988) proposed that renal 
vasodilation to histamine was dependent on an intact 
endothelium and the biosynthesis of EDRF, first described
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by Furchgott & Zawadzki in 1980. EDRF has since been 
identified as NO by Palmer et al. (1987) which is derived 
from L-arginine by NO synthase (Palmer et al., 1988).
There is plentiful evidence for the role of a relaxing 
factor(s) derived from the endothelium in the relaxation 
of vascular smooth muscle to histamine. In the isolated 
rat thoracic aorta (Van de Voorde & Leusen, 1983a), 
guinea-pig pulmonary artery (Satoh et al., 1984) and 
human pulmonary artery (Ortiz et al., 1992), receptor 
dependent relaxation was abrogated by mechanical removal 
of the endothelium. Similarly, H2 receptor dependent 
vasodilation of the rabbit cerebral artery was 
circumvented by endothelial denudation (Sercombe et al.,
1986) . In addition, mechanical removal of the endothelium 
in the dog mesenteric artery reduced the vasodilator 
response to histamine (Toda, 1984). Indeed, Hide et al. 
(1988) have demonstrated the presence of receptors on 
both the endothelium and vascular smooth muscle of the 
guinea-pig aorta and there is evidence of site dependent 
relaxant and constictor effects of receptor 
stimulation in the rabbit cerebral artery (Kim et al.,
1986) and guinea-pig pulmonary artery (Satoh et al.,
1984) . Toda (1984) was able to block vasodilation of the 
dog mesenteric artery to histamine with indomethacin and 
suggested that prostacyclin release from both endothelial 
and vascular smooth muscle sources was involved. In the 
human pulmonary artery (Ortiz et al., 1992), endothelium-
18
dependent vasodilation to receptor stimulation was 
abolished by a combination of indomethacin and L-NAME or 
L-NOARG. The endothelium-dependent vasodilation of the 
rabbit cerebral artery to H3 receptor stimulation was
similarly attenuated by indomethacin and dexamethasone,
• • c*suggesting prostacyclin release, and L-NAME and N -
monomethyl-L-arginine (L-NMMA), indicating NO release
(Kim et al., 1992).
Given the availability of agents which selectively 
inhibit the biosynthesis of NO such as L-NAME and L-NOARG 
(Rees, 1990; Moore et al., 1990), it was important to 
investigate whether EDRF(NO)-dependence for renal 
vasodilation to histamine in the preconstricted rat 
isolated perfused kidney could be demonstrated with these 
more selective tools. In addition, given the ability of 
histamine to stimulate the release of prostacyclin from 
cultured human umbilical endothelial cells (Baenziger et 
al., 1981; McIntyre et al., 1985), a role for vasodilator 
cyclo-oxygenase products in the mediation of renal 
vasodilation to histamine was investigated using 
indomethacin.
1.7. Further aspects of histamine pharmacology
Histamine is a biogenic amine with diverse 
pharmacological actions which are mediated by three known
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classess of receptors: H1-H3 (for review, see Hill 1990). 
A typical response allied to receptor stimulation 
concerns the contraction of smooth muscle (pig trachea 
(Driver et al., 1987);, guinea-pig ileum and trachea 
(Arunlakshana and Schild, 1959; Dews and Graham, 1946) ; 
guinea-pig pulmonary artery (Satoh et al., 1984); rabbit 
cerebral artery (Kim et al., 1986)). Postcapillary 
venular endothelial cells may also be contracted in 
response to receptor stimulation (Majno et al., 1969). 
However, H^ receptor stimulation may also lead to the 
relaxation of smooth muscle in a host of isolated tissues 
(see above), including the methacholine-preconstricted 
guinea-pig trachea (Undem et al., 1987). In this study, 
histamine-mediated tracheal relaxation was independent of 
catecholamine release and the epithelium and sensitive to 
inhibition by indomethacin (Undem et al., 1987).
The stimulation of H^ receptors is associated with the 
activation of phospholipase C and phosphoinositide 
hydrolysis, leading to the formation of IP3 and DAG in a 
variety of tissues including endothelial cells (Lo & Fan,
1987), vascular (Lonchampt et al., 1988) and visceral 
smooth muscle (Jafferji & Michell, 1976). For reviews of 
IP3 and DAG as second messengers, see Berridge et al. 
(1984; 1993).
20
A typical response allied to H2 stimulation concerns the 
relaxation of smooth muscle (guinea-pig lung parenchyma 
(Foreman et al., 1985); rabbit mesenteric artery 
(Reinhardt & Ritter, 1979); rabbit cerebral artery 
(Sercombe et al., 1986); feline cerebral artery (Edvinson 
et al., 1983); human temporal artery (Ottosson et al., 
1989)). The stimulation of H2 receptors is associated 
with the activation of adenyl cyclase in a variety of 
tissues including vascular smooth muscle (Reinhardt & 
Ritter, 1979), airway smooth muscle (Eyre & Chand, 1982) 
and cardiac muscle (Hattori et al., 1991). This leads to 
the intracellular accumulation of cyclic adenosine 
monophosphate (cAMP). Within smooth muscle, cAMP 
activates protein kinase-dependent phosphorylation, which 
leads to relaxation through the inhibition of myosin 
light chain kinase activity (Silver & Still, 1982) , 
membrane hyperpolarisation (Fujiwara et al., 1988; Kume 
et al., 1989) and internal calcium sequestration (Mueller 
& Van Breeman, 1979).
The H3 receptor was first described as a presynaptic 
autoreceptor in the rat cerebral cortex (Arrang et al.,
1983) and has since been described in the human cerebral 
cortex (Arrang et al., 1988), the guinea-pig iluem 
(Trzeciakowski, 1987), guinea-pig airways (Ichinose et 
al., 1989) and the guinea-pig mesenteric artery (Ishikawa 
& Sperelakis, 1987) . The first case of a postjuntional H3 
receptor was reported in the rabbit cerebral artery (Kim
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& Oudart, 1988). Documented responses to H3 receptor 
stimulation include the inhibition of neurotransmitter 
histamine synthesis and release (Arrang et al., 1987), 
the inhibition of sympathetic (Ishikawa & Sperelakis,
1987), cholinergic (Ichinose & Barnes, 1989) and non- 
adrenergic non-cholinergic transmission (Taylor & 
Kilpatrick, 1992) and arterial vasodilation (Kim et al., 
1988; 1992). The second messenger system(s) associated 
with H3 receptors remains to be elucidated.
It was therefore of additional interest to explore the 
relative contributions made by the three documented 
classes of histamine receptor to renal vasodilation to 
histamine in the isolated perfused rat kidney.
1.8. Polymorphonucleocytes (PMNs) and vascular 
dysfunction after ischaemia/reperfusion
A feature commonly associated with the reperfusion of 
ischaemic tissue is a histologically demonstrable 
accumulation of PMNs, as in the ischaemic/reperfused dog 
and rat myocardium (Romson et al., 1983; Engler et al., 
1986; Hale & Kloner, 1991; Smith III et al., 1988) and 
canine gracilis muscle (Walden et al., 1990). The 
ischaemic/reperfused rat kidney in vivo is no exception 
with a histologically verifiable PMN accumulation 
reported to occur in the inner stripe of the outer
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medulla within 5 min of reperfusion after 45 min renal 
artery occlusion (Willinger et al., 1992). Within 2h 
reperfusion, PMN accumulation was predominant in the 
cortex and outer stripe of the outer medulla (Willinger 
et al., 1992). Reperfusing PMNs have been implicated in 
both myocardial infarction (Romson et al., 1983; Engler 
et al., 1986; Bednar et al., 1985; Smith III et al.,
1988), coronary vascular endothelial injury (Sheridan et 
al., 1991; Kloner et al., 1991), ischaemic bowel injury 
(Hernandez et al., 1987) and skeletal muscle contractile 
dysfunction following ischaemia/reperfusion (Carden et 
al., 1990; Walden et al., 1990). While the benefits of 
PMN depletion to postocclusive renal function in the rat 
are equivocal (Thornton et al., 1989; Paller et al.,
1986; Klausner et al., 1989), this intervention has been 
reported to improve renal blood flow after 45 min 
occlusive renal ischaemia/reperfusion in the rat in vivo 
(Klausner et al., 1989).
A postocclusive perfusion defect located in both the 
outer and inner medulla has been well documented in the 
rat kidney in vivo and leads to the phenomenon of ,fno 
reflow" after ischaemia. The perfusion defect involves 
intravascular congestion with erythrocytes (Vetterlein et 
al., 1986; Mason et al., 1987) and probably also PMNs 
(Hellberg et al., 1990) and possibly in addition, tubular 
epithelial swelling with subsequent encroachment on the 
lumens of peritubular capillaries and the venous vasa
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recta (Yamamoto et al., 1984). An increase in 
microvascular permeability and a loss of cell volume 
regulation during ischaemia leads to renal oedema and 
heamoconcentration (Flores et al., 1972; Vetterlein et 
al., 1986). Interestingly, fibrin deposition has been 
reported to contribute to ischaemic renal oedema in the 
rat in vivo (Druid & Rammer, 1992) while thrombin is not 
thought to play a role in medullary erythrocyte 
congestion (Mason et al., 1987). The "no reflow" 
phenomenon has also been described in the ischaemic 
canine myocardium in vivo where it has been variously 
attributed to straightforward tissue necrosis (Darsee & 
Kloner, 1980), capillary plugging with PMNs (Engler et 
al., 1983) and myocardial oedema (Kloner et al., 1974). A 
prime role for PMN vascular plugging was proposed in the 
globally ischaemic isolated perfused rat heart where 
exogenous, reperfusing PMNs enhanced coronary vascular 
resistance by reducing capillarity (Reynolds & McDonagh,
1989). There is evidence from the ischaemic canine 
myocardium that the expression of the "no reflow" 
phenomenon is related to the period of ischaemia (Kloner 
et al., 1974).
The role of PMNs in renal vascular dysfunction following 
ischaemia/reperfusion may not be restricted to 
rheological capillary plugging and the "no reflow" 
phenomenon. PMNs are capable of producing tissue damage 
by the release of cytotoxic species such as oxygen free
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radicals and degradative enzymes and furthermore release 
vasoactive arachidonate metabolites (for reviews, see 
Mehta et al., 1988; Harlan, 1987; Korthuis & Granger, 
1993; Downey, 1990; Rowe et al., 1984; Werns & Lucchesi, 
1988; Kukreja & Hess, 1992). PMNs may therefore modulate 
vascular reactivity via effects on vascular smooth muscle 
integrity, microvascular permeability and the metabolism 
of endothelial vasoactive autacoids in addition to direct 
effects through the production of vasoactive mediators.
The salutary effect of PMN depletion in the rat on 
postocclusive renal blood flow reported by Klausner et 
al. (1989), was associated with reduced renal venous 
levels of thromboxane B2 . Complimentary to this finding, 
the thromboxane A2 synthase inhibitor, DP-1904, has been 
demonstrated to attenuate the postocclusive rise in renal 
vascular resistance in the anaesthetised rat (Masumara et 
al., 1991). Other direct vasoconstrictors elaborated by 
PMNs include platelet activating factor (Tippins et al., 
1992) and peptido-leukotrienes. Angiotensin II and 
endothelin-1 may also be formed by PMN-mediated, 
enzymatic cleavage of angiotensinogen (Wintroub et al., 
1984) and big-endothelin-1 (Sessa et al., 1991), 
respectively. In addition, canine PMNs may elicit 
endothelium-dependent constriction of the isolated canine 
femoral artery via the endothelial uptake and metabolism 
of PMN-derived leukotriene A4 to peptido-leukotrienes 
(Gonzales et al., 1992). Furthermore, PMNs may interact
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with platelets to promote vasoconstriction (Sessa &
Mullane, 1990).
Accounting for an indirect vasoconstrictor effect of PMNs 
is their potential to inactivate NO via the production of 
the superoxide anion (Gryglewski, 1987; Tsao & Lefer,
1990). This is thought to account for the endothelium- 
dependent and superoxide dismutase-sensitive constriction 
of the isolated rabbit aorta to PMNs (Ohlstein et al., 
1989) . Furthermore, the presence of superoxide anion is 
responsible for the PMN-mediated loss of endothelium- 
dependent vasodilation in the isolated bovine and rat 
mesenteric artery (De Kimpe et al., 1993; Karasawa et 
al., 1991). Another aspect of PMN-impaired endothelial 
vasodilator function is an enhanced reactivity to 
vasoconstrictors (De Kimpe et al., 1992). Despite these 
pro-vasoconstrictor effects, there is some evidence that 
at least human and rat PMNs may also elaborate a 
modulatory vasorelaxing factor similar to NO (Mehta et 
al., 1989; Rimele et al., 1987) while rat PMNs in 
addition may produce endothelium-dependent vasodilation 
(Grossman & Zambetis, 1989).
The finding by Augustin & Lutz (1991) that lipid 
peroxidation accompanies rat renal occlusive 
ischaemia/reperfusion in vivo coupled with the 
demonstration by Paller et al. (1984) that oxygen free 
radicals contribute to postocclusive renal dysfunction
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and a raised renal vascular resistance in the rat in 
vivo, may admit a role for PMNs as a potential source of 
such radicals. In support of this, Linas et al. (1988) 
have shown that exogenous, reperfusing PMNs enhanced 
renal dysfunction in the isolated perfused rat kidney 
previously made ischaemic by renal artery occlusion in 
vivo and that the oxygen free radical scavengers 
dimethylthiourea and catalase were protective. Extensive 
endothelial damage was recorded after renal ischaemia and 
reperfusion both in vivo (Paller et al., 1984) and in 
vitro (Linas et al., 1988), while the latter group 
reported damage to vascular smooth muscle specific to 
reperfusion with exogenous PMNs in vitro. It was noted 
that despite these findings, basal renal vascular 
resistance was unaltered by reperfusing PMNs (Linas et 
al., 1988). However, it has been shown in both the 
isolated perfused rabbit and rat heart that activated 
PMNs may indeed raise coronary vascular tone via the 
production of oxygen free radicals (Gillespie et al., 
1986; Semb et al., 1989). One possibility is that oxygen 
free radicals stimulate the production of thromboxane A 2 
(Tate et al., 1984). Linas et al. (1992) have 
subsequently found that rat kidneys made mildly ischaemic 
in vivo can activate reperfusing primed PMNs in vitro to 
release oxygen free radicals and elastase, leading to 
impaired renal function. It was previously recorded by 
Welbourn et al. (1991) that PMN-derived oxygen free 
radicals and elastase may synergise to produce
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permeability oedema in the lung after hindlimb ischaemia 
in the rat.
1.9. PMN infiltration
The infiltration of tissue by PMNs proceeds by three 
major contiguous events: rolling adhesion of PMNs to the 
vascular endothelium or margination; shear-stress 
resistant or firm adhesion of PMNs; and PMN migration 
across the endothelial monolayer. The endothelium plays 
an active role in PMN infiltration from the recruitment 
of PMNs via the production of chemotactic cytokines such 
as interleukin-8 (IL-8 ) and melanoma growth-stimulating 
activity (MGSA) to the development of a proadhesive state 
(for reviews, see Lefer & Lefer, 1993; Mantovani et al., 
1992; Pober & Cotran, 1990). Adhesion molecules of the 
selectin family, the f^-integrin subfamily and the 
immunoglobulin family orchestrate these events (for 
reviews, see Springer (1990), Carlos & Harlan (1990), 
Harlan & Liu (1992), Mackay & Imhof (1993) , Zimmerman
(1992), Kayestha (1992) and Shimizu (1992)).
The B2~integrins are leukocyte surface glycoprotein 
heterodimers consisting of a common 95KDa B-subunit 
(CD18) and one of three variable a-subunits, designated 
CDlla (177KDa), CDllb (165KDa) and CDllc (150KDa)
(Albelda & Buck, 1990). The combinations engender LFA-1
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(CDlla/CD18), Mac-1 (CDllb/CD18) andpl50,95 
(CDllc/CD18). The immunoglobulin, intercellular adhesion 
molecule 1 (ICAM-1) acts as an endothelial ligand for 
leukocyte LFA-1 and Mac-1 (Diamond, 1990; Patarroyo & 
Makgoba, 1989; Smith et al., 1988). The importance of 
CD18 and ICAM-1 in vitro to the firm adherence of both 
stimulated PMN to quiescent endothelial cells (Lo et al., 
1989; Mulligan et al., 1992; Smith et al., 1989;
Zimmerman & McIntyre, 1988) and unstimulated PMN to 
activated endothelial cells (Furie et al., 1991;
Luscinkas et al., 1989; Pohlman et al, 1986) has been 
amply demonstrated. Moreover, Argenbright et al. (1991) 
have shown that the adherence of stimulated PMN to the 
vascular endothelium of the rabbit mesenteric vasculature 
in situ is CD18- and ICAM-1-dependent. Furthermore, 
monoclonal antibodies (MoAbs) against CD18 have been 
reported to reduce tissue PMN infiltration both in 
response to the intraderma1 injection of a range of 
inflammatory mediators (Arfors et al., 1987; Rampart & 
Williams, 1988) and following ischaemia and reperfusion, 
as in the dog myocardium (Tanaka et al., 1993), rabbit 
lung (Horgan et al., 1990), cat myocardium (Ma et al.,
1991) and cat mesentery (Oliver et al., 1991). In vitro, 
Barton et al. (1989) have demonstrated that the 
infiltration by PMNs in the isolated inflamed rabbit lung 
is attenuated by MoAbs against CD18 and ICAM-1 adhesion 
molecules. In addition to the role of B2”^n‘^e9r^ns an<* 
ICAM-1 in firm adhesion, there is also evidence that
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these adhesion molecules facilitate transendothelial 
migration (Kavanaugh et al., 1991; Parkos et al., 1991; 
Smith et al., 1988).
1.10. Assessment of myeloperoxidase (MPO) activity in 
renal tissue after ischaemia/reperfusion in vivo: effects 
of antibodies against adhesion molecules used by PMNs
Myeloperoxidase, a characteristic constituent of PMNs 
(Bradley et al., 1982a; Schultz and Kaminker, 1962), has 
been used as a biochemical marker for the tissue content 
of PMNs. The established photometric assay of MPO employs 
o-dianisidine as the hydrogen donor for H2O2 (Bradley et 
al., 1982b). However, TMB may be used as a 
noncarcinogenic alternative hydrogen donor for the 
determination of peroxidase (Bos et al., 1981; Andrews 
and Krinsky, 1981; Holland et al., 1974) and can be shown 
to provide a more sensitive assay of human MPO than o- 
dianisidine (Suzuki et al., 1983). In an attempt to 
extend these findings, the sensitivities of TMB and o- 
dianisidine assays were directly compared in an assay of 
MPO derived from rat blood PMNs.
Polymorphonucleocyte (PMN) infiltration as assessed by 
tissue MPO assay has been shown in numerous tissues 
including the inflamed rat dermis (Bradley et al.,
1982b), the ischaemic/reperfused dog and rabbit 
myocardium (Bednar et al., 1985; Mullane et al., 1985;
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1987; Schierwagen et al., 1990), rat intestine (Grisham 
et al., 1986; Karasawa et al., 1991; Krawisz et al.,
1984), rat liver (Augustin & Lutz, 1991) and dog gracilis 
muscle (Korthuis et al., 1988). A potential problem 
concerned with the assessment of MPO in renal tissue is 
that peroxidase activity may be effectively inhibited by 
renal tissue factors (Schierwagen et al., 1990; Hillegas 
et al., 1990; Ormrod et al., 1987). Schierwagen et al. 
(1990) have speculated that these factors may include 
H2O2 consuming systems. The aim of the present study was 
to employ measures that would overcome these peroxidase 
inhibitory factors. To this end, the recovery of 
exogenous horseradish peroxidase activity added to rat 
renal tissue was assessed as an index of inhibition. The 
validity of these measures was demonstrated by 
delineating a time course of renal PMN accumulation after 
45min renal ischaemia and various periods of reperfusion 
in vivo. It was of further interest to investigate a role 
for adhesion molecules in renal PMN accumulation after 
ischaemia/reperfusion using recently available murine 
MoAbs against rat intercellular adhesion molecule-1 
(ICAM-1) and rat CD18 of B2”inte9rins (Tamatani & 
Miyasaki, 1990; Issekutz & Issekutz, 1992).
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2 • Methods
2.2. Rat model of ischaemia/reperfusion in vivo at Bath 
University
Male Wistar rats of Bath University Animal House stock 
weighing 250-300g maintained on standard laboratory chow 
and allowed water ad libitum, were anaesthetised with 
Hypnorm (fentanyl, 0.315mg/ml & fluanisone, 
lOmg/ml)/Hypnovel (midazolam, 5mg/ml) (3.3ml/kg i.p. of a 
solution comprising 1 pt Hypnorm, 1 pt Hypnovel, 2 pts 
sterile water) and placed on a warming pad at 37°C. 
Prolonged anaesthesia was afforded by the administration 
of Hypnorm (0.3ml/kg i.m.) every 30min following the 
initial dose of Hypnorm/Hypnovel (Flecknell, 1987) . For a 
review of neuroleptanalgesia, see Green (1978). Following 
the administration of heparin (200U/kg via tail vein) in 
0.9% (w/v) saline, the peritoneal cavity was opened by a 
midline abdominal incision and the renal arteries located 
by blunt dissection. Intestinal disturbance was kept to a 
minimum. Renal ischaemia was produced by left renal 
pedicle occlusion with a non-traumatic vascular clamp for 
30min. The right sham-operated kidney served as a 
control. Reperfusion for 15min was elected by removal of 
the clamp.
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2.2. Isolated perfused kidney technique
The cannulation of the renal arteries for renal perfusion 
in vitro was essentially as described by Nishiitsutso-Uwo 
et al. (1967), Schurek et al. (1975) and Linas et al. 
(1981). Briefly, the left renal artery was cannulated 
first with a Portex (OD 0.63mm) luer fitting catheter 
after ligation of the aorta between the origins of the 
right and left renal arteries. The right renal artery was 
cannulated via the superior mesenteric artery after 
ligation of the proximal aorta and adrenal artery.
Kidneys were rapidly excised and perfused by a Watson- 
Marlow type MHRE 200 flow inducer in open circuit at 
6ml/min with Krebs Henseleit solution (KHS) (pH 7.4) 
warmed to 37°C and gassed with 95% oxygen/ 5% carbon 
dioxide. The KHS was prefiltered through a pore size of 
ll/urn to remove gross particulate matter. In early trials, 
in-line filters (0.4 5-0.8/m) soon became fouled and had 
to be discarded. The composition of KHS was (in mM) :
NaCl, 143; KC1, 4.7; KH2P04, 1.2; MgS04, 1.2; NaHC03, 25; 
CaCl2 , 1.2; glucose, 11.7. Renal perfusion pressure was 
monitored with a Gould pressure transducer and displayed 
on a Gould 2200S chart recorder. Since flow rate was 
constant, changes in perfusion pressure were taken to 
reflect changes in renovascular resistance. Perfused 
kidneys were allowed to stabilise for 30min before 
interventions. Bolus doses were injected through the
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kidney via an injection port in a volume which did not 
affect perfusion pressure (50/xl) .
2.3. Assessment of renal water content
Rat kidneys were first weighed wet, incubated at 60°C for 
12h in an oven and then re-weighed to provide dry weight. 
The water content was assessed as the difference between 
wet and dry weights.
2.4. Renal vasodilation to histamine
Preparations were preconstricted with either methoxamine 
(3/xM, Burton et al., 1990) or an equieffective 
concentration of potassium (30mM) and vasodilator 
responses (expressed as a percentage reduction in 
elevated perfusion pressure) to histamine (l-300nmoles), 
and papaverine (l-300nmoles) and acetylcholine (0.03-3 
nmoles) as comparisons, were assessed.
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2.5. Effects of NO synthase and cyclo-oxygenase 
inhibitors and histamine receptor antagonists on renal 
vasodilation to histamine
Two submaximal doses of histamine (10, 30nmoles) together 
with two doses of papaverine as internal controls 
(30nmoles papaverine equiactive with 30nmoles histamine 
and lOOnmoles papaverine providing a maximal dilation) 
which gave reproducible responses with time, were 
subsequently employed to assess renal vasodilation to 
histamine and papaverine in potassium(3OmM)- or 
methoxamine (3/xM)-preconstricted preparations before and 
during perfusion with NO synthase or cyclo-oxygenase 
inhibitors or histamine receptor antagonists. In 
addition, a submaximal dose of acetylcholine (0.3nmoles 
eliciting 60% of Emax) was used to provide NO-dependent 
renal vasodilation in methoxamine (3/xM)-preconstricted 
preparations. Vasodilator responses in these studies were 
expressed as a percentage of the maximal response to 
lOOnmoles papaverine.
The pA2 for ranitidine was estimated from a functional 
inhibition curve after Hill plot transformation, using 
dose-ratio analysis analogous to the Gaddum equation 
essentially as described by Lazareno & Birdsall 
(1993a;b).
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2 .6 . Vasoconstriction to endothelins and effects of BQ123 
and indoemethacin
An assessment of vasoconstrictor reactivity to 
endothelin-1 ET-1 (l-100pmoles), ET-2 (l-100pmoles) and 
ET-3 (l-100pmoles) was made in an attempt to profile the 
major ET/SX receptor subtype responsible. Three doses 
each of ET-1 and ET-3 (3,10,30pmoles) were subsegently 
chosen to assess vasoconstriction to ET-1 or ET-3 during 
perfusion with BQ123 (1/xM, Ihara et al., 1992b; T616maque 
et al., 1993) or indomethacin (10/xM, Stier et al., 1992). 
Comparisons were made with separate time-matched control 
preparations. Any effect of interventions on non-specific 
vasoconstrictor reactivity was assessed by examining the 
vasoconstrictor response to a lOmin perfusion with 
modified KHS containing HOmM KCl.
2.7. Renal vasoconstrictor reactivity in vitro after 
ischaemia in vivo
Vasoconstrictor reactivity to ET-1 (3-30pmoles), ET-3 (3- 
30pmoles), noradrenaline (l-300nmoles), 5- 
hydroxytryptamine (1-100 nmoles) , and KCl (110 mM) was 
assessed in the isolated perfused kidney after 30min 
renal ischaemia or 30min normoperfusion as control, in 
vivo.
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2.8. Isolation of rat blood PMNs
Blood collected from a carotid artery into heparin 
(lOU/ml) from male CD Wistar rats anaesthetised with 
Sagatal (60mg/kg i.p.) was carefully layered onto Ficoll- 
Paque lymphocyte separation medium and spun at 300g for 
30min. The lower ruddy layer was mixed with an equal 
volume of 1.8% (w/v) dextran in isotonic, pH7.4 phosphate 
buffered saline (PBS) and left to sediment for 40min. The 
resultant upper layer was spun at 200g for lOmin and the 
pellet resuspended in first 5.8ml 0.21% (w/v) NaCl and 
then 0.5ml 1M KCl to lyse remaining erythrocytes. After 
washing in PBS, viable cells were enumerated in a 
Neubauer haemocytometer following dilution with 0.1%
(w/v) trypan blue. Differential cell counts indicated the 
yield for PMNs to be routinely >90%. Samples were diluted 
in PBS to provide lxlO6 PMNs/ml.
2.9. Extraction of MPO from rat blood PMNs
Aliqouts of PMNs (Ixl06-lxl05) were transferred to vials 
and the volume subsequently made up to 5ml with 
hexadecyltrimethylammonium bromide (HTAB) in 50mM pH6.0 
phosphate buffer to give a final concentration of 0.5% 
(w/v) . PMN suspensions were then disrupted for 30s using 
a Branson sonicator at 20% power and subsequently snap 
frozen in liquid nitrogen and thawed on three consecutive
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occasions before a final 30s sonication. PMN suspensions 
were then incubated at 60°C for 2h (see below) to verify 
the heat resistance of MPO (Schierwagen et al., 1990). 
Incubated PMN suspensions were spun at 4000g for 12min 
and the MPO-rich supernate collected and stored at -22°C 
until assay.
2.10. Assay of MPO from rat blood PMNs
MPO was assayed photometrically in a 96-well plate 
incubated at 37°C using a Dynatech MR7000 plate reader 
controlled by a Toshiba 1000 microprocessor. The TMB 
assay of MPO was essentially as described by Suzuki et 
al. (1983) . The assay mixture consisted of 20/il MPO-rich 
supernate, 10/il TMB (final concentration 1.6mM) dissolved 
in dimethylsulphoxide (DMSO) and 70/xl H2O2 (final 
concentration 0.3mM) diluted in 80mM phosphate buffer 
pH5•4. The o-dianisidine assay of MPO was essentially as 
described by Bradley et al. (1982b). The assay mixture 
consisted of 20/il MPO-rich supernate and 80/xl H2O2 (final 
concentration 0.147mM) diluted in 50mM phosphate buffer 
pH6 .0 containing o-dianisidine dihydrochloride (final 
concentration 0.526mM). The reaction was initiated by the 
addition of H2O2 and the increase in absorbance was 
determined over 3min at 30s intervals at either 630nm 
(TMB) or 460nm (o-dianisidine).
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2,11, Recovery of exogenous horseradish peroxidase 
activity from rat renal supernate
As an index of the inhibition of peroxidase activity by 
renal tissue, the recovery of exogenous horseradish 
peroxidase activity was assessed from renal supernate 
derived from non-ischaemic rat kidneys in a photometric 
assay using TMB. The activity of exogenous horseradish 
peroxidase in the presence of 0.5% (w/v) HTAB was defined 
as 100% recovery. In an attempt to enhance the recovery 
of exogenous horseradish peroxidase activity from renal 
supernate, the renal supernate was heat-inactivated by 
incubating at 60°C for 2h in a water bath (Schierwagen et 
al., 1990) and/or the assay H2O2 concentration was raised 
10-fold. The assay mixture consisted of 10/xl TMB (final 
concentration 1.6mM) dissolved in DMSO, 50/il H2O2 (final 
concentration 0.3 or 3.0mM) diluted in 80mM phosphate 
buffer pH5.4, 20/xl heat-inactivated or untreated renal 
supernate or 20jil 0.5% (w/v) HTAB (as control) and 20/il 
horseradish peroxidase diluted as for H2O2 (final 
concentration 8 .7-43.3/ug/l) . Horseradish peroxidase 
activity was expressed as the initial rate of change in 
absorbance (£A/min) per unit concentration of enzyme 
(lmg/1 ).
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2.22. Determination of molar absorption coefficient for 
TMB-dehydrogenation product
TMB present over a range of initial concentrations was 
dehydrogenated by H2°2 the presence of excess 
horseradish peroxidase activity and the peak absorbance 
increase determined at 630nm. The assay mixture consisted 
of 10/xl TMB (final concentration 0.2-1.6mM) dissolved in 
DMSO, 70/xl H2O2 (final concentration 0.04-0.3mM) and 20/il 
horseradish peroxidase (final concentration 41.6mg/l) 
diluted in 80mM phosphate buffer, pH5.4. The ratio of 
TMB:H202 was maintained at 5.3:1 to avoid the oxidation 
of TMB-dehydrogenation product by excess H2O2 .
2.13. Rat model of renal ischaemia/reperfusion in vivo at 
Roche Research Centre
Male CD Wistar rats (300-400g) were anaesthetised with 
Sagatal (60mg/kg i.p.) and the body temperature 
maintained at 37°C by a warming pad. Both kidneys were 
exposed via flank incisions and kept moist with warmed 
0.9% (w/v) saline. After the administration of heparin 
(200U/kg via tail vein), the left renal pedicle was 
occluded by an atraumatic vascular clamp for 45min. 
Reperfusion was elected for 0.5-6h by removal of the 
clamp and visually confirmed before postischaemic and 
sham-operated kidneys were restored to the body cavity
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and the wounds sutured. Temgesic (0.5mg/kg s.c.) was 
administered upon reperfusion to provide post-operative 
analgesia. Renal reperfusion was terminated by cervical 
dislocation of the animal. Kidneys were then excised, 
blotted dry and weighed. Kidneys were subsequently 
immersed in 0.5% (w/v) HTAB in 50mM phosphate buffer 
pH6 .0 and stored at -22°C until MPO extraction and assay.
2.14. Renal MPO extraction
Frozen rat kidneys were thawed at room temperature and 
macerated with an Ultra-Turrax T25 blender for 30s.
Sample volumes were then made up to 10ml with 0.5% (w/v) 
HTAB before disruption and freeze-fractionation as 
described for the extraction of MPO from rat blood PMNs. 
Samples were incubated at 60°C for 2h in a water bath and 
then spun at 4000g for 12min. The supernate was collected 
for MPO assay.
2.15. Renal MPO assay
Renal MPO activity was assessed photometrically at 630nm 
as described for the assessment of rat blood PMN MPO 
activity using TMB as substrate. The assay mixture 
consisted of 20/xl heat-inactivated renal supernate, lOjil 
TMB (final concentration 1.6mM) dissolved in DMSO and
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7O/xl H2O2 (final concentration 3.0mM) diluted in 80mM 
phosphate buffer pH5.4. Renal MPO activity was expressed 
in units (U) where 1U represents that amount of enzyme 
degrading 1/xmole H2 0 2/min under the stated conditions.
MPO activity was standardised with respect to the wet 
weight of the sham-operated kidney.
2.16, Effect of monoclonal antibodies (MoAbs) against 
adhesion molecules used by PMNs on renal MPO activity
Murine anti-rat ICAM-1 or murine anti-rat CD18 MoAb was 
administered to animals both 5min before 45min renal 
ischaemia (20jLig/kg via tail vein) and at the commencement 
of lh reperfusion (20jug/kg via tail vein) in vivo. The 
isotype-matched antibody murine IgG^ or an unrelated 
murine antibody, IgG2a/ was also administered in an 
identical manner to serve as controls. Vehicle control 
animals received 0.9% (w/v) saline (0.5ml/kg via tail 
vein) at the appropriate time points. Sham-operated 
contralateral kidneys provided control preparations for 
ischaemic/reperfused kidneys.
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2.17. Effect of murine IgGi on recovery of exogenous 
horseradish peroxidase activity from rat renal supernate
In order to examine the possibility that murine 
antibodies might directly affect tissue peroxidase 
activity, the recovery of exogenous horseradish 
peroxidase activity was assessed from renal supernate 
derived from non-ischaemic kidneys exposed to murine IgG^ 
(40/xg/kg i.v. total) in vivo. The activity of horseradish 
peroxidase in the presence of 0.5% (w/v) HTAB was defined 
as 1 0 0% recovery.
2.18. Fluorescence activated cell sorting (FACS) analysis
Aliquots of rat blood PMNs (0.5xl06 cells) were suspended 
in 50/xl PBS/0.2% (w/v) sodium azide together with 4/xg of 
anti-ICAM-1 or anti-CD18 MoAb or murine IgG^ or IgG2a 
antibody and incubated at -4°C for 30min. Cell 
suspensions were then washed twice in 1ml PBS/0.2% (w/v) 
sodium azide and resuspended in 50/xl PBS/0.2% (w/v) 
sodium azide together with 0.5/xg fluorescently labelled 
bovine anti-murine IgG R-phycoerythrin conjugate F(ab')2 
fragment and incubated at -4°C for 30min. Cells were then 
washed twice and finally resuspended in PBS/0.2% (w/v) 
sodium azide and stored at -4°C until FACS analysis using 
a Becton Dickenson FACSar.
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2.19. Pharmacological agents and solutions
Agents used were noradrenaline bitartrate, acetylcholine 
hydrochloride, histamine hydrochloride, mepyramine 
maleate, ranitidine hydrochloride, 5-hydroxytryptamine 
creatinine sulphate, verapamil hydrochloride, NG-nitro-L- 
arginine methyl ester, NG-nitro-L-arginine, heparin 
sodium, ascorbic acid and indomethacin (Sigma), 
thioperamide hydrochloride (Research Biochemicals Inc.)/ 
endothelins-1, -2 -3 (Novabiochem), BQ123 (Peninsula), 
murine anti-rat-ICAM-l and murine anti-rat-LFA-1 B chain 
(anti-CD18) MoAbs (British Biotechnology), murine IgG^, 
murine IgG2a an<* bovine anti-mouse IgG R-phycoerythrin 
conjugate F(ab')2 fragment (Sigma Immunochemicals),
3,3•,5,5•-tetramethylbenzidine, o-dianisidine 
hydrochloride, Type II horseradish peroxidase, 
dimethylsulphoxide, sodium azide and
hexadecyltrimethylammonium bromide (Sigma), Giemsa stain, 
trypan blue, hydrogen peroxide, dextran (250KDa), sodium 
di-hydrogen phosphate monohydrate, di-sodium hydrogen 
phosphate hexahydrate (British Drug House), sterile 0.9% 
(w/v) saline (Fresenius), Temgesic (buprenorphine 
hydrochloride) (Reckitt and Colman), Sagatal 
(pentobarbitone sodium) (May and Baker) and Ficoll-Paque 
(Pharmacia). Indomethacin was dissolved with an equal 
amount of di-sodium carbonate in 0.9% (w/v) saline. All 
other agents were dissolved in 0.9% (w/v) saline and 
agents to be perfused were diluted to the working
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concentration in KHS. Solutions of noradrenaline were 
made up in 0.9% (w/v) saline containing O.lmM ascorbate. 
Modified KHS containing 30 or llOmM KCl was prepared by 
including the desired quantity of KCl and osmotically 
adjusting by proportionately reducing the content of 
NaCl.
2.20. Statistics
The comparison of two group means was conducted using 
Student's t-test (Matthews & Farewell, 1988). The 
comparison of multiple group means was made using 1 way 
analysis of variance (1W-AN0VA) while the comparison of 
repeated measures was conducted using 2W-AN0VA (Bailey, 
1981; Snedecor & Cochran, 1980). The comparison of a 
control group mean with each of a number of treatment 
group means was conducted using Dunnett's test (Tallarida 
& Murray, 1981; Wallenstein, 1980). Curve fitting was 
conducted according to the method of least squares and 
preceded linear regression analysis (Goldstein, 1964).
The comparison of slopes of linear regression lines was 
conducted using Student's t-test for parallelism 
(Tallarida & Murray, 1981). Values are mean ± standard 




3.1. Renal vasodilation to histamine and papaverine
When rat kidneys were perfused at 6ml/min, basal renal 
perfusion pressure was in the range 70-90 mmHg. Sustained 
elevations in perfusion pressure obtained with either 
potassium (30mM) or methoxamine (3/liM, Burton et al.,
1990) were in the range 135-220 mmHg. Preconstriction 
with methoxamine (3/zM) was often unstable (Figure 2) . 
Preconstriction with phenylephrine (0.5/zM, Oyekan et al.,
1991), noradrenaline (0.5/xM, Bhardwaj & Moore, 1988), 
angiotensin II (lOOnM, Scholz & Kurtz, 1990) and 
endothelin-1 (3-100 pmoles, Baydoun et al., 1989) was 
also found to be unstable in pilot studies of 1-2 
preparations only.
Histamine (l-300nmoles) (Figure 3) and papaverine (1- 
300nmoles) (Figure 4) elicited dose-dependent reductions 
in perfusion pressure elevated to the same level with 
either potassium (3 0mM) or methoxamine (3/xM) (Figure 5) . 
The ED50 for histamine against potassium-induced tone 
(7.5±1.Onmoles, n=2 0) was not significantly different 
from the ED50 for histamine against methoxamine-induced 
tone (9.7±2.Inmoles, n=8 ). However, vasodilator responses 
to histamine (l-3 00nmoles) were significantly depressed 
in potassium(3OmM)-preconstricted preparations when
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Figure 2. Representative trace showing aberrant 
vasoconstrictor responsiveness to methoxamine (3jxM) in 






Figure 3. Vasodilation to histamine (HA) in the isolated 
perfused rat kidney preconstricted with methoxamine (3/xM) 
(n=8 ) (open circles) or potassium (30mM) (n=20) (closed
circles) . Methoxamine (3/xM) and potassium (30mM) elevated 
perfusion pressure (PP) to 173±9 (n=8 ) and 166±6 (n=20) 
mmHg, respectively. Decreases in PP are expressed as a 
percentage reduction in elevated PP. ★p<0.01 with 
respect to vasodilator responses in methoxamine (3/xM) - 





Figure 4. Vasodilation to papaverine (PAP) in the 
isolated perfused rat kidney preconstricted with 
methoxamine (3/xM) (n=5) (open circles) or potassium
(30mM) (n=14) (closed circles) . Methoxamine (3/zM) and
potassium (30mM) elevated perfusion pressure (PP) to 
157±9 (n=5) and 175±9 (n=14) mmHg, respectively. 
Decreases in PP are expressed as a percentage reduction 
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Figure 5. Experimental trace showing vasodilation to 
histamine (l-300nmoles) and papaverine (l-300nmoles) in 
the isolated perfused rat kidney preconstricted with 

























compared to methoxamine(3juM) -preconstriction (Figure 3). 
In contrast, vasodilator responses to papaverine were 
identical in potassium-preconstricted (£0 5 0=2 1 .512.5 
nmoles, n=14; Emax=4012%, n=14) and methoxamine- 
preconstricted (ED5 q=2 0 .3±4.6nmoles, n=5; Emax=40±2%, 
n=5) preparations. Acetylcholine (0.03-3nmoles) elicited 
dose-dependent reductions in perfusion pressure elevated 
with methoxamine (3juM) (ED5q=0 . 15±0.02nmoles, n=5;
Emax=24±2 /^ n=5) (Figure 6 ). Vasodilator responses to 
acetylcholine (0.03-3nmoles) were poorly graded and 
significantly depressed in potassium-preconstricted 
preparations (n=15) (Figure 6 ) .
3.2. Effects of histamine receptor antagonists on renal 
vasodilation to histamine
Ranitidine (0.1-10/xM) significantly depressed 
vasodilation to 30nmoles histamine in a concentration- 
dependent manner and effectively abolished the response 
at 10/xM (97% inhibition, n=7) (Figure 7) . The pA2 for 
ranitidine was estimated to be 6.6710.09 (n=7) from the 
functional inhibition curve. Vasodilator responses to 
30nmoles papaverine (equiactive with 30nmoles histamine) 
(Figure 7) and lOOnmoles papaverine were not diminished 
in the presence of ranitidine (0.1-10^M).
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Figure 6 . Vasodilation to acetylcholine (ACh) in the 
isolated perfused rat kidney preconstricted with 
methoxamine (3/zM) (n=5) (open circles) or potassium 
(30mM) (n=15) (closed circles) . Methoxamine (3/liM) and
potassium (30mM) elevated perfusion pressure (PP) to 
177±7 (n=5) and 162±5 (n=15) mmHg, respectively. 
Decreases in PP are expressed as a percentage reduction 
in elevated PP. ★ p<0.01 with respect to vasodilator 
responses in methoxamine (3/zM) -preconstricted 






Figure 7. Functional inhibition curve featuring 
vasodilation to histamine (HA) (30nmoles) (filled 
circles) and papaverine (PAP) (30nmoles) (open circles) 
in the potassium(3OmM)-preconstricted isolated perfused 
rat kidney in the presence of graded concentrations of 
ranitidine (0.1-10/iM) (n-7). Decreases in perfusion 
pressure (PP) are expressed as a percentage of the 
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Mepyramine at 1/xM, a concentration presumed to produce 
effective receptor blockade (Hill & Young, 1980; Van 
de Voorde & Leusen, 1983b), significantly depressed but 
did not abolish, vasodilation to histamine (10, 30nmoles) 
(Figure 8 ). Vasodilation to 30nmoles papaverine 
equiactive with 30nmoles histamine was unaffected by this 
concentration of mepyramine. Thioperamide at 10/*M did not 
significantly affect vasodilation to histamine (1 0 , 
30nmoles) or papaverine (30nmoles) (Figure 8 ). This 
concentration of thioperamide has been shown to fully 
reverse the histamine-mediated presynaptic inhibition of 
depolarisation-induced histamine release from rat brain 
slices (Arrang et al., 1987).
3.3. Effects of L-NAME, L-NOARG and indomethacin on 
elevated renal perfusion pressure
Perfusion pressure in potassium(3OmM)-preconstricted 
preparations before and after L-NAME (0.3mM) was 186±9 
and 193±9mmHg, respectively (P>0.05, n=5). Perfusion 
pressure before and after L-NAME (0.3mM) in 
methoxamine (3juM)-preconstricted preparations was 192±4 
and 187±4mmHg, respectively (P>0.05, n=6 ). In contrast to 
the inefficacy of L-NAME (0.3mM), L-NOARG (0.3mM) raised 
perfusion pressure by 62±12 mmHg from 145±8 to 207±8 mmHg 
(P<0.01, n=6 ) in potassium(3OmM)-preconstricted 
preparations. Indomethacin (IOjxM, Stier et al., 1992)
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Figure 8 . Vasodilation to histamine (HA) (10, 30nmoles) 
and papaverine (PAP) (30nmoles) in the potassium(3OmM)- 
preconstricted isolated perfused rat kidney before (n=ll) 
(open bars) and during perfusion with mepyramine (1/iM) 
(closed bars) (n=6 ) or thioperamide (10/xM) (cross-hatched 
bars) (n=5). Decreases in perfusion pressure (PP) are 
expressed as a percentage of the maximal decrease in PP 
obtained with lOOnmoles PAP. ★p<0.05 with respect to 
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significantly decreased perfusion pressure by 18±5mmHg 
from 145±4 to 127±4mmHg (P<0.01, n=6 ) in potassium(3OmM)- 
preconstricted preparations.
3.4. Effects of L-NAME, L-NOARG and indomethacin on renal 
vasodilation to histamine
Vasodilation to histamine (10, 30nmoles) was unaffected 
by L-NAME (0.3mM), L-NOARG (0.3mM) or indomethacin (IOjzM) 
in potassium(3OmM)-preconstricted preparations (Figure 9) 
and furthermore was unaffected by L-NAME (0.3mM) in 
methoxamine (3/xM)-preconstricted preparations (Figure 10). 
The vasodilator response to a submaximal dose of 
acetylcholine (0.3nmoles eliciting 60% of E^x) was 
however significantly diminished by L-NAME (0.3mM) in 
methoxamine (3/xM)-preconstricted preparations (Figure 10). 
The vasodilator response to acetylcholine (0.3nmoles) was 
unchanged in the time-matched control group (23±2% vs 
25±2% of a lOOnmoles papaverine response, P>0.05, n=6 ) .
3.5. Renal vasoconstriction to ET-1, ET-2 and ET-3
ET-1, ET-2 and ET-3 elicited similar, dose-dependent 
increases in perfusion pressure over the same dose range 
(1-100 pmoles) (Figure 11). The Emax for ET-1, ET-2 and 
ET-3 was 153±11 (n=6 ) , 159±12 (n=4) and 167±9 mm Hg (n=5)
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Figure 9. Vasodilation to histamine (HA) (10, 30nmoles) 
and papaverine (PAP) (30nmoles) in the potassium(3OmM)- 
preconstricted isolated perfused rat kidney before (open 
bars) (n=17) and during perfusion with L-NAME (0.3mM) 
(closed bars) (n=6), L-NOARG (cross-hatched bars) (n=6 ) 
or indomethacin (10/xM) (diagonal bars) (n=6 ) . Decreases 
in perfusion pressure (PP) are expressed as a percentage 
of the maximal decrease in PP obtained with lOOnmoles 

































































Figure 10. Vasodilation to acetylcholine (ACh)
(0.3nmoles), histamine (HA) (10, 30nmoles) and papaverine 
(PAP) (30nmoles) in the methoxamine (3/xM) -preconstricted 
isolated perfused rat kidney before (open bars) (n=6 ) and 
during perfusion with L-NAME (0.3mM) (closed bars) (n=6 ). 
Decreases in perfusion pressure (PP) are expressed as a 
percentage of the maximal decrease in PP obtained with 
lOOnmoles PAP. ★  P<0.01 with respect to vasodilator 




































Figure 11. Vasoconstriction to endothelin-1 (ET-1) (open 
circles) (n=6), ET-2 (triangles) (n=4) and ET-3 (closed 
circles) (n=5) in the isolated perfused rat kidney. Basal 




















(P>0.05). Elevations in perfusion pressure due to ETs 
were transient. The time to 75% recovery from comparable 
peak rises in perfusion pressure due to ETs was 
significantly abbreviated for 30pmoles ET-3 relative to 
30pmoles ET-1 and ET-2 (Figures 12 & 13).
3.6. Effect of BQ123 on renal vasoconstriction to ET-1 
and ET-3
BQ123(l/iM, T61emaque et al., 1993; Ihara et al., 1992b) 
showed no effect on either basal perfusion pressure or 
the non-specific vasoconstriction to KCl(llOmM). Basal 
perfusion pressure in the presence and absence of 
BQ123 (1/iM) was 70±3 (n=6 ) and 79±8 mmHg (n=6 ) , 
respectively (P>0.05). KCl(llOmM) raised perfusion 
pressure by 116±3 (n=6 ) and 112±8 mmHg (n=6 ) in the
■m
presence and absence of BQ123(l/xM), respectively 
(P>0.05). Peak vasoconstriction to the lower doses of ET- 
1 examined was significantly depressed by BQ123(1/liM) 
(Figure 14). In addition, the time to 75% recovery from 
the peak rise in perfusion pressure due to 30pmoles ET-1 
was significantly attenuated in the presence of ET^ 
receptor blockade (Figures 15 & 16) . Indeed, the time to 
75% recovery from peak vasoconstriction to 30pmoles ET-1 
and 30pmoles ET-3 was similar in the presence of BQ123 
(1/xM) . Peak rises in perfusion pressure due to 30pmoles 
ET-1 and ET-3 in the presence and absence of BQ123(l/xM)
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Figure 12. The time to 75% recovery from peak 
vasoconstrictor responses to endothelin-1 (ET-1) (open 
bars) (n=6 ), ET-2 (closed bars) (n=4) and ET-3 (cross- 
hatched bars) (n=5) in the isolated perfused rat kidney.






















Figure 13. Experimental trace showing rises in perfusion 
pressure (PP) due to (A) endothelin-1 (ET-1), (B) ET-2
















Figure 14. Rises in perfusion pressure (PP) to 
endothelin-1 (ET-1) in the isolated perfused rat kidney 
in the absence (open bars) (n=6 ) or presence (closed 
bars) (n=6 ) of BQ123 (1/iM) . ★P<0.05 with respect to the 


















Figure 15. The time to 75% recovery from peak 
vasoconstrictor responses to endothelin-1 (ET-1) and ET-3 
(both 30pmoles) in the isolated perfused rat kidney in 
the absence (open bars) (n=6 ) or presence (closed bars) 
(n=6 ) of BQ123 (1/xM) . ★p<0.01 with respect to ET-1 
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Figure 16. Experimental trace showing rises in perfusion 
pressure (PP) due to endothelin-1 (ET-1) (3-30pmoles) in 
the isolated perfused rat kidney in the absence (A) and 












were not significantly different. Peak vasoconstriction 
to ET-3 (3-30pmoles) was not significantly affected by 
BQ123 (1/xM) (Figure 17).
3.7. Effect of indomethacin on renal vasoconstriction to 
ET-1 and ET-3
Indomethacin (10/xM) showed no effect either on basal 
perfusion pressure or the non-specific vasoconstriction 
to KCl(llOmM). Basal perfusion pressure in the presence 
and absence of indomethacin (10/xM) was 78±4 (n=6 ) and 76±4 
mmHg (n=6 ), respectively (P>0.05). KCl(llOmM) raised 
perfusion pressure by 119±8 (n=6 ) and 115±10 mmHg (n=6 ) 
in the presence and absence of indomethacin (10/xM)
(P>0.05). Neither peak vasoconstriction to ET-1 (Figure 
18) nor ET-3 (Figure 19) (3-30pmoles) was significantly 
affected by indomethacin (10/xM) . The time to 75% recovery 
from the peak rise in perfusion pressure due to ET-1(30 
pmoles) (23.2±4.5 min, n=6 ) remained significantly 
greater than that for ET-3 (30pmoles) (9.7±2.0 min, n=6 ) 
in the presence of indomethacin (10/xM) (P<0.05).
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Figure 17. Rises in perfusion pressure (PP) to 
endothelin-3 (ET-3) in the isolated perfused rat kidney 
in the absence (open bars) (n=6 ) or presence (closed 
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Figure 18. Rises in perfusion pressure (PP) due to 
endothelin-1 (ET-1) in the isolated perfused rat kidney 
in the absence (open bars) (n=6 ) or presence (closed 


















Figure 19. Rises in perfusion pressure (PP) due to 
endothelin-3 (ET-3) in the isolated perfused rat kidney 
in the absence (open bars) (n=6 ) or presence (closed 


















3.8. Effects of renal ischaemia/reperfusion in vivo on 
renal vasoconstriction to noradrenaline, 5- 
hydroxytryptamine and KC1
Dose-response series were generated in the isolated 
perfused rat kidney to noradrenaline (l-300nmoles) and 5- 
hydroxytryptamine (l-100nmoles) after 30min renal 
ischaemia with or without 15min reperfusion in vivo. 
Dose-response series to noradrenaline (l-300nmoles) or 5- 
hydroxytryptamine (l-100nmoles) were repeated lh later to 
assess reproducibility. Isolated perfused rat kidneys 
that were normoperfused in vivo for 30min or 45min served 
as time-matched control preparations (see Figure 20).
3.9. Effect of 30min renal ischaemia in vivo on renal 
vasoconstriction to noradrenaline, 5-hydroxytryptamine 
and KC1
Basal perfusion pressure was initially 78±3 (n=8 ) and 
83±4 mmHg (n=6 ) in the 30min renal ischaemia and control 
group, respectively (P>0.05). At the end of some 2h 
perfusion, basal perfusion pressure was 61±3 (n=8 ) and 
77±4 mmHg (n=6 ) in the 30min renal ischaemia and control 
group, respectively (P>0.05). The water content of 
isolated perfused rat kidneys in each group after this 
time was 85.5±0.4% which was significantly higher than
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Figure 20. Experimental trace showing rises in perfusion 
pressure (PP) due to (A) 5-hydroxytryptamine (1- 
lOOnmoles) and (B) noradrenaline (l-300nmoles) in the 
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the water content of nonperfused kidneys (76.7±0.2%, 
n=24, P<0.01).
The ED50 for noradrenaline (l-300nmoles) during the 
initial dose-response series in vitro after 30min renal 
ischaemia in vivo was 2-fold higher (11.4±2.0 nmoles, 
n=8 ) than in the normoperfused control group (5.1±2.0 
nmoles, n=6 ), but statistical significance was not 
attained (Figure 21). However, when a second dose- 
response series to noradrenaline (l-300nmoles) was 
repeated lh later in the 30min renal ischaemia group, the 
ED50 was found to have significantly decreased with time 
from 11.4±2.Onmoles to 2.6±2.Onmoles (P<0.025, n=8 ). In 
contrast, the ED50 for noradrenaline (l-300nmoles) in the 
control group was not found to significantly vary between 
the initial and repeated dose-response series. 
Vasoconstriction to noradrenaline (l-300nmoles) was 
similar in the 30min ischaemia and control groups during 
the repeated dose-response series lh later (Figure 22).
To investigate whether the apparently depressed potency 
of noradrenaline observed during the initial dose- 
response series in vitro after 30min renal ischaemia in 
vivo might be selective for this agonist, an initial 
dose-response series to 5-hydroxytryptamine (l-1 0 0nmoles) 
was generated. 30min renal ischaemia in vivo showed no 
effect to depress vasoconstriction to 5-hydroxytryptamine 
(l-1 0 0nmoles) when this agonist rather than noradrenaline
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Figure 21. Rises in perfusion pressure (PP) due to 
noradrenaline (NA) during the initial dose-response 
series in the isolated perfused rat kidney after 30min 
renal ischaemia (open symbols) (n=8 ) or normoperfusion 
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Figure 22. Rises in perfusion pressure (PP) due to 
noradrenaline (NA) during the second dose-response series 
in the isolated perfused rat kidney after 30min renal 
ischaemia (open symbols) (n=8 ) or normoperfusion (closed 














was employed in the initial dose-response series (Figure 
23). The ED50 for 5-hydroxytryptamine was identical in 
the 30min renal ischaemia group (4.0±1.Onmoles, n=4) and 
control group (4.0±0.9nmoles, n=4) (P>0.05) during the
initial dose-response series. Moreover, the potency of 5- 
hydroxytryptamine did not significantly vary in vitro 
with time (lh) in the 30min renal ischaemia group. In 
addition, 30min renal ischaemia in vivo had no 
significant effect on the non-specific vasoconstriction 
to KC1 (30mM). KC1 (30mM) in the 30min renal ischaemia 
and control group raised perfusion pressure by 74±4 (n=6 ) 
and 63±6 mmHg (n=6), respectively (P>0.05).
3.10. Effect of 30min renal ischaemia and 15min 
reperfusion in vivo on renal vasoconstriction to 
noradrenaline
Vasoconstriction to noradrenaline (l-300nmoles) examined 
during the initial dose-response series after 30min renal 
ischaemia/15min reperfusion was similar to that after 
45min normoperfusion in vivo (Figure 24). The ED50 for 
noradrenaline in the 30min renal ischaemia/15min 
reperfusion and control group was 4.5±1.6 (n=6 ) and 
4.2±1.Onmoles (n=6) , respectively (P>0.05), during the 
initial dose-response series and 3.9±1.6 (n=6 ) and 
2.9±1.Onmoles (n=6), respectively (P>0.05), during the 
repeated dose-response series lh later. The ED50 for
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Figure 23. Rises in perfusion pressure (PP) due to 5- 
hydroxytryptamine (5-HT) during the initial dose-response 
series in the isolated perfused rat kidney after 30min 
renal ischaemia (open symbols) (n=4) or normoperfusion 





















Figure 24. Rises in perfusion pressure (PP) due to 
noradrenaline (NA) in the isolated perfused rat kidney 
during the initial dose-response series after 30min renal 
ischaemia followed by 15min reperfusion (open symbols) 
(n=6) or 45min normoperfusion (closed symbols) (n=6) in 












noradrenaline in the 30min renal ischaemia/15 min 
reperfusion group did not significantly vary over lh 
perfusion.
3.11. Effect of 30min renal ischaemia in vivo on renal 
vasoconstriction to ET-1 and ET-3
Basal perfusion pressure in the 30min renal ischaemia and 
control groups was in the range 70-90 mmHg. 30min 
ischaemia in vivo had no effect on dose-dependent 
vasoconstrictor responses to ET-1 (3-30pmoles) (Figure 
25) or ET-3 (3-30pmoles) (Figure 26). Furthermore, the 
time to 75% recovery from peak vasoconstrictor responses 
to ETs was unaffected by previous 30min renal ischaemia 
in vivo.
3.12. Assessment of MPO activity
In order to investigate the presence of accumulated PMNs 
after renal ischaemia/reperfusion in vivo, renal MPO 
activity was assessed as a biochemical marker of PMNs.
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Figure 25. Rises in perfusion pressure (PP) due to 
endothelin-1 (ET-1) in the isolated perfused rat kidney 
after 30min renal ischaemia (closed bars) (n=6) or 



















Figure 26. Rises in perfusion pressure (PP) due to 
endothelin-3 (ET-3) in the isolated perfused rat kidney 
after 30min renal ischaemia (closed bars) (n=6) or 
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3.13. Assay of MPO derived from rat blood PMNs
MPO activity from rat blood PMNs was linearly correlated 
with PMN number from which MPO was extracted in either an 
assay using TMB (r=1.000, P<0.01, n=5) or o-dianisidine 
(r=0.998, P<0.01, n=5) (Figure 27). However, the TMB 
assay of PMN-derived MPO was 3-fold more sensitive than 
the o-dianisidine assay (51.83±1.56 <SA/min/106 PMNs 
compared to 18.08±1.07 aA/min/106 PMNs, P<0.01, n=5). The 
more sensitive TMB assay was therefore adopted in 
subsequent studies.
3.14. Recovery of exogenous horseradish activity from rat 
renal supernate
The initial rate of increase of absorbance at 630nm was 
linearly correlated with the concentration of horseradish 
peroxidase in the well (8.7-43.3jug/l) . The activity of 
exogenous horseradish peroxidase added to renal supernate 
derived from non-ischaemic rat kidneys was significantly 
depressed (P<0.01, n=4) compared to the activity of 
exogenous horseradish peroxidase activity added to an 
equal volume of 0.5% HTAB (Figure 28) and represented a 
recovery of approximately only 9% (i.e. 91% inhibiiton). 
The activity of exogenous horseradish peroxidase added to 
renal supernate incubated at 60°C for 2h was still 
significantly depressed (P<0.01, n=4). Similarly, when
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Figure 27. Myeloperoxidase (MPO) activity derived from 
rat blood polymorphonucleocytes assessed as the initial 
rate of change of absorbance (£A/min), using 3,3*,5,5*- 
tetramethylbenzidine (solid line) (n=5) or o-dianisidine 
(dashed line) assays (n=5). ★ p <0.05 with respect to o- 
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Figure 28. Horseradish peroxidase activity assessed as 
the initial rate of change of absorbance ($A/min) per 
unit concentration of enzyme in the presence of 0.5% 
(w/v) HTAB/50mM pH6.0 phosphate buffer (control, open 
bars) (n=4) or rat renal supernate either incubated at 
60°C for 2h (cross-hatched bars) (n=4) or unincubated 
(closed bars) (n=4): effects of 0.3 or 3.0mM hydrogen 
peroxide in assay. ★ p<0.01 with respect to appropriate 

































h2°2 was employed at a 10-fold higher concentration in 
the assay (3.0mM), the activity of exogenous horseradish 
peroxidase activity added to untreated renal supernate 
remained significantly reduced (P<0.01, n=4) . However, 
when H2O2 was present in the assay at 3. OmM and the renal 
supernate had been heat inactivated, the activity of 
exogenous horseradish peroxidase activity was not 
significantly different from the appropriate control 
activity. No peroxidase activity could be detected in 
heat-inactivated renal supernate per se in the absence of 
exogenous horseradish peroxidase.
3.15. Determination of molar absorption coefficient for 
TMB-dehydrogenation product
The peak absorbance values at 630nm were linearly 
correlated with the initial concentration of TMB (0.2- 
1.6mM) (r=1.000, P<0.01, n=3) (Figure 29). The molar
absorption coefficient for TMB-dehydrogenation product 
was estimated to be 3152.5±5.0 (n=3).
3.16. Renal MPO activity and wet weight after 
ischaemia/reperfusion in vivo
When renal supernate was assayed under conditions where 
the recovery of exogenous horseradish peroxidase activity
Ill
Figure 29. Determination of molar absorption coefficient 
for 3,3•,5,5•-tetramethylbenzidine (TMB) dehydrogenation 
product: peak absorbance (A) at 630nm versus initial 




















was near 100%, i.e. 2h incubation at 60°C and 3.0 iH 
assay H2O2 , kidneys undergoing 45min (but not 30min) 
ischaemia and 1, 3 or 6h reperfusion in vivo showed 
significant MPO activity (Figure 30), indicating tissue 
PMN accumulation. MPO activity in sham-operated kidneys 
was undetectable. Furthermore, MPO activity was 
undetectable in kidneys undergoing 45min ischaemia and 1 
or 3h reperfusion when assayed under conditions where the 
recovery of exogenous horseradish peroxidase activity was 
only 9%, i.e. no heat inactivation and 0.3 mM assay H2O2 
incubation. The wet weight of kidneys undergoing 45min 
ischaemia and 0.5-6h reperfusion in vivo was 
significantly increased as a percentage of the wet weight 
of sham-operated kidneys (Figure 31). Left kidney wet 
weight was 99.8±2.5% of the right kidney wet weight in a 
random sample of animals (n=6).
3.17. Effects of antibodies against adhesion molecules 
used by PMNs on renal MPO activity after 
ischaemia/reperfusion in vivo
Treatment of animals with anti-ICAM-1 or anti-CD18 MoAb 
(20/xg/kg via tail vein both 5min before renal ischaemia 
and at the commencement of reperfusion was associated 
with significantly reduced MPO activity in kidneys 
undergoing 45min ischaemia and lh reperfusion in vivo 
(Figure 32). In addition, identical treatment with the
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Figure 30. Myeloperoxidase (MPO) activity in rat kidneys 
after 45min renal ischaemia and various periods of 
reperfusion in vivo expressed per unit wet weight of the 
sham-operated kidney. ★p<0.05 with respect to zero MPO 












Figure 31. Wet weight of rat kidneys after 45min renal 
ischaemia and various periods of reperfusion in vivo as a 
percentage of the wet weight of sham-operated kidneys.














Figure 32. Effects of monoclonal antibodies (MoAbs) 
against rat CD18 of 8 2-integrins and rat intercellular 
adhesion molecule-1 (ICAM-1) or the isotype-matched 
control antibody murine IgG^ and an unrelated murine 
IgG2a antibody or saline vehicle, on myeloperoxidase 
(MPO) activity in rat kidneys after 45min ischaemia and 
lh reperfusion in vivo. Antibodies were administered both 
5min before renal ischaemia (20/zg/kg i.v.) and at the 
commencement of reperfusion (20/xg/kg i.v.). Saline 
vehicle was administered (0.5ml/kg i.v.) at identical 
time points. ★p<0.05 with respect to 
ischaemic/reperfused renal MPO activity with no 














no intervention saline anti-CD  18 anti-ICAM -1
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isotype-matched control antibody murine IgG^ or an 
unrelated murine IgG2a antibody produced a similar 
effect. In contrast, MPO activity in kidneys undergoing 
45min ischaemia and lh reperfusion in animals receiving 
vehicle alone in vivo (0.5ml/kg via tail vein of 0.9% 
(w/v) saline) was not significantly affected. MPO 
activity in sham-operated kidneys was undetectable in 
these experiments. Antibody interventions (40/ig/kg i.v. 
total) did not significantly affect increases in the wet 
weight of rat kidneys undergoing 45min ischaemia and lh 
reperfusion in vivo.
3.18. Effect of murine IgGj on recovery of exogenous 
horseradish peroxidase activity from rat renal supernate
To investigate whether a murine antibody preparation 
could directly affect the photometric assay of 
peroxidase, the recovery of exogenous horseradish 
peroxidase activity added to rat renal supernate derived 
from non-ischaemic kidneys exposed to murine IgG^ 
(40/xg/kg i.v. total) in vivo was assessed. The recovered 
activity was not significantly different from 1 0 0%.
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3.19. FACS analysis
In an investigation of whether murine antibodies could 
non-specifically recognise a common binding site on the 
surface of PMNs, a FACS analysis demonstrated a clear 
dextral shift in the the population density binding anti- 
CD18 MoAb relative to anti-ICAM-1 MoAb or murine IgG^ or 
IgG2a antibodies (Figure 33).
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Figure 33. Fluorescence activated cell sorting (FACS) 















4.1. Vasodilation to histamine in the isolated perfused 
rat kidney: roles of NO, cyclo-oxygenase products and H^, 
H2  and Hj receptors
The reason(s) for the often unstable nature of 
methoxamine-induced renal vascular tone observed during 
studies of vasodilator reactivity, may possibly include: 
an a^-adrenoceptor-mediated variable release of 
vasoactive prostaglandins (Cooper & Malik, 1985); a 
heterogenous and variable dilator response of the renal 
vasculature to a^-adrenoceptor-mediated rises in renal 
perfusion pressure (Burton et al., 1989); and a renal 
autoregulatory capacity (see Vander, 1971; de Wardener, 
1985). Those periods during this study when methoxamine- 
induced renal vascular tone was reproducibly stable, may 
conceivably be accounted for by a seasonal variability in 
the animals and/or a change in animal site services.
Histamine acted as a dilator of the rat renal 
microvasculature when vascular tone was induced by 
preconstriction. The reason for the enhanced efficacy of 
histamine and acetylcholine as vasodilators when tone was 
induced with methoxamine rather than potassium is 
unclear. However, differences in non-specific vasodilator 
reactivity can probably be ruled out since reactivity to
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the directly acting vasodilator papaverine was equivalent 
vis-A-vis potassium- and methoxamine-induced tone. One 
possibility for both histamine and acetylcholine is that 
these vasodilator agonists are able to differentiate 
between agonist- and depolarisation-induced vascular tone 
at the second messenger level (see van Breeman et al«, 
1986; Nishimura et al., 1989). Potassium depolarisation 
has previously been shown to inhibit responses to 
acetylcholine (Noll et al., 1991) while the second 
messenger associated with EDRF(NO), cyclic guanosine 
monophosphate (cGMP) (Murad et al., 1985; Rapoport & 
Murad, 1983) has been reported to be less effective in 
reversing vascular tone due to depolarisation than to a- 
adrenoceptor stimulation (Lincoln et al., 1983; Hester et 
al., 1979; 1988). Another consideration concerns a 
potentially heterogenous effect of both contractile 
agonists and vasodilators in terms of which renal 
resistance vessels are preferentially preconstricted by 
the former and which resistance vessels are 
preferentially dilated by the latter (Cairns et al.,
1989; 1991). One additional possibility for histamine, is 
that methoxamine-induced tone may permit indirect 
vasodilation due to a histamine-stimulated release of 
catecholamines from adrenergic nerve terminals (Balfagon 
et al., 1984); while depolarisation with potassium might 
be expected to stimulate the release of adrenergic 
catecholamines per se and thereby deny this mechanism to 
histamine.
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The pA2 value of 6.67 estimated for ranitidine in the 
present study from a functional inhibition curve, is in 
close agreement with the pA2 (6.70) obtained for this H2 
receptor antagonist by Cavanagh et al. (1983) in the 
guinea-pig atrium using Schild analysis. Furthermore, 
vasodilation to histamine (30nmoles) was effectively 
abolished by ranitidine (10/xM) while vasodilation to an 
equieffective dose of papaverine (30nmoles) was 
unaffected. These findings clearly implicate 
predominantly H2 receptors in the subservance of 
vasodilation to histamine in the isolated perfused rat 
kidney. The finding that vasodilation to histamine was 
also partially sensitive to mepyramine (1/xM) suggests 
that Hi stimulation also promotes renal vasodilation 
while the ineffectiveness of thioperamide (10/iM) provides 
evidence that H3 receptors are not involved. The use of 
selective agonists at: Hi receptors, such as 2- 
pyridylethylamine and 2-methylhistamine; H2 receptors, 
such as dimaprit and impromodine; and at H3 receptors, 
such as R(-)-a-methylhistamine (see Hill, 1987; Arrang et 
al., 1987), would help to further elucidate the roles of 
these receptors in renal vasodilation to histamine.
L-NAME (0.3mM) and L-NOARG (0.3mM), failed to reduce 
vasodilation to histamine in the isolated perfused rat 
kidney, preconstricted either by depolarisation or by 
adrenoceptor stimulation. Both L-NOARG and L-NAME are 
potent inhibitors of NO synthase in vitro (Moore et al.,
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1990; Rees et al., 1990) while L-NAME has the advantage 
of being more readily soluble. In contrast to the 
findings of Bhardwaj & Moore (1988) with less selective, 
presumed EDRF(NO) inhibitors, the present study with more 
selective tools therefore suggests that EDRF(NO) is not a 
mediator of vasodilation to histamine in the 
preconstricted isolated perfused rat kidney. The reason 
for the discrepancy between findings may concern a non- 
selective action of putative EDRF(NO) inhibitors or 
conceivably, methodological differences or a divergence 
in the mechanism(s) of renal vasodilation to histamine 
between the rat strains used. Evidence of significant NO 
synthase inhibition in the present study was provided 
both by the depression of vasodilation to acetylcholine 
(0.3nmoles) by L-NAME (0.3mM) in the methoxamine- 
preconstricted isolated perfused rat kidney and by the 
rise in perfusion pressure accompanying L-NOARG in 
potassium-preconstricted preparations.
Paradoxically and despite several reports that basal NO 
release regulates renovascular resistance in rats (Welch 
et al., 1991; Radermacher et al., 1990; Tolins et al., 
1990), no elevation in perfusion pressure was observed 
with L-NAME (0.3mM). This fact may be attributable to the 
anomalously high preconstricted perfusion pressures 
observed in preparations to be exposed to L-NAME which, 
while allowing for the observation of vasodilator 
responses, might have functionally antagonised further
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rises in tone due to the loss of an endogenous 
vasodilator. Conceivable alternative explanations are 
that reputed isoenzymes of NO synthase responsible for 
basal and agonist-stimulated EDRF(NO) release may be 
differentially affected by L-arginine analogues (Frew et 
al., 1993; Crack & Cocks, 1992) or that L-NOARG may raise 
tone by an action independent of the inhibition of NO 
synthase (Cocks & Angus, 1991). The present results with 
L-NAME are supported by Farhat et al. (1990) who reported 
the ability of another NO synthase inhibitor, NG- 
monomethyl-L-arginine (L-NMMA), to inhibit endothelium- 
dependent vasodilation in the absence of an effect to 
raise tone in the -agonist-preconstricted isolated 
perfused rat kidney.
The failure of indomethacin (10/xM) to reduce vasodilation 
to histamine in the potassium-preconstricted isolated 
perfused rat kidney, additionally suggests that cyclo- 
oxygenase products may be ruled out as vasodilator 
mediators. Bhardwaj & Moore (1988) reached a similar 
conclusion with indomethacin in the a^-adrenoceptor- 
preconstricted isolated perfused rat kidney. However, the 
vasodilator effect of indomethacin per se in the present 
study does argue for either a basal or depolarisation- 
stimulated release of a vasoconstrictor prostanoid, 
possibly prostaglandin E2 (see Baer & McGiff, 1979).
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The notion that vasodilation in the rat isolated perfused 
kidney may involve vascular H3 receptors functionally 
coupled to EDRF(NO) and prostacyclin release, a mechanism 
previously described in the rabbit cerebral intracranial 
artery by Kim et al. (1992), is clearly refuted by the 
ineffectiveness of the H3 receptor antagonist 
thioperamide in conjunction with the inability of the NO 
synthase inhibitors L-NAME and L-NOARG and the inability 
of the cyclo-oxygenase inhibitor indomethacin, to 
modulate renal vasodilation to histamine.
The endothelium as a potential source of vasodilator 
mediators other than EDRF(NO) and cyclo-oxygenase 
products, cannot be excluded by the present study. As an 
alternative explanation to endothelial involvement, 
histamine could elicit vasodilation via a direct action 
on histaminergic receptors on vascular smooth muscle to 
raise intracellular levels of cyclic adenosine 
monophosphate (cAMP) (Hill, 1987; Reinhardt & Ritter, 
1979) .
Taken together, the available evidence indicates that 
neither EDRF(NO) nor cyclo-oxygenase products act as 
mediators of the vasodilation to histamine in the 
preconstricted isolated perfused rat kidney and 
furthermore suggest that this vasodilator response is 
predominantly subserved by H2 receptors.
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4.2. Vasoconstriction to endothelins in the isolated
perfused rat kidney: effects of BQ123 and indomethacin
Two main findings from the relatively simple isolated 
perfused kidney preparation in vitro support the 
contention by Cristol et al. (1993b) in vivo that renal 
vasoconstriction to ETs/SXs is mediated by a 
heterogeneous population of non-ET^, possibly ETg 
receptors in addition to ET^ receptors in the rat. 
Firstly, ETs were equipotent as vasoconstrictors in the 
isolated perfused rat kidney which is consistent with a 
family-common ETg receptor-mediated event (Sakurai et 
al., 1990). The present report of equipotency of ETs as 
renal vasoconstrictors is in agreement with the findings 
of Evangelista et al. (1992). Secondly, a selective 
antagonist at ET^ receptors, BQ123 (Ihara et al., 1992a; 
Nakamichi et al., 1992), significantly depressed peak 
vasoconstriction to ET-1 at the lower doses. In addition, 
BQ123 significantly abbreviated the time to 75% recovery 
from peak vasoconstriction to ET-1 at the highest dose of 
ET-l examined.
It is doubtful if BQ123 at a higher concentration than 
ljuM would have exerted any additional selective 
depression of the vasoconstrictor responses to ET-1.
BQ123 is a potent ET^ receptor antagonist which displaces 
1 2 5 [ET-1] binding to ET^ receptors in cultured porcine 
aortic smooth muscle membranes with an IC50 of 22nM
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(Ihara et al., 1992a). 1 2 5 [ET-1] displacement is maximal 
at 1/xM BQ123. Furthermore, the results of these 
displacement studies are in good agreement with the 
functional inhibition by BQ123 of the contraction of the 
porcine coronary artery to ET-1 (pA2 7.4). As BQ123 
begins to displace 1 2 5 [ET-1] binding to ETg sites in 
porcine cerebellar membranes at concentrations greater 
than ljuM (Ihara et al., 1992a), the use of higher 
concentrations could result in non-specific actions and 
was therefore not justified.
The sensitivity of vasoconstriction to only the lower 
doses of ET-1 to BQ123 in the isolated perfused rat 
kidney, agrees well with the report by Cristol et al. 
(1993b) that renal vasoconstriction to higher doses of 
ET-1 in rats in vivo are insensitive to BQ123 while the 
responses to lower doses of ET-1 are diminished. The 
explanation provided by Cristol et al. (1993b) that the 
stimulation of ET^ receptors may be important in the 
mediation of a constrictor event to low doses of ET-1 but 
that an alternative, non-ET^-mediated constrictor event 
may supervene at high doses, may explain the present 
findings.
BQ123 dramatically reduced the time to recovery from peak 
vasoconstriction to 30pmoles ET-1. Indeed, this parameter 
for 30pmoles ET-1 was reduced by some 70% after ET^ 
receptor blockade while the peak rise in perfusion
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pressure was not significantly reduced (see Figures 13 & 
14). This finding is evocative of the report by Bigaud 
and Pelton (1992) that the duration, but not the 
magnitide, of the renal vasoconstrictor response to the 
reputed ETg-selective agonist [Ala1 '3 •1 1 '1 5 ]ET-1 (Saeki 
et al., 1991) is reduced by BQ123 in the anaesthetised 
rat. This clearly raises the possibility that an 
essentially BQ123-insensitive vasoconstrictor event can 
nonetheless be modified by an action at ET^ receptors. In 
the present study, the suggestion is that the occupation 
of ET^ receptors prolongs the duration of 
vasoconstriction to at least higher doses of ET-1.
Indeed, the time to 75% recovery from comparable peak 
vasoconstrictor effects of ET-1 and ET-3 (both 30pmoles) 
was similar in the presence of BQ123. The shorter-lived 
vasoconstrictor response to ET-3 relative to ET-1 and ET- 
2 at least at higher doses and the insensitivity of its 
time to 75% recovery to BQ123 may well reflect the much 
lower affinity of ET-3 for ET^ receptors (Ihara et al., 
1992a). These findings help to rule out suggestions that 
a differential release of a vasodilator such as PGI2 
(Trybulec et al., 1991) or any other vasodilator may play 
a role in the relatively short-lived duration of 
vasoconstriction to ET-3 (30pmoles). In further support 
of this, indomethacin failed to significantly modulate 
vasoconstriction to ET-1 or ET-3. It is however still 
possible that ET-stimulated prostanoid release could
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occur in the absence of an influence on vasoconstrictor 
reactivity (Stier et al., 1992).
The transience of the vasoconstriction to bolus doses of 
ETs in the rat isolated perfused kidney is in contrast to 
the prolonged responses observed in the isolated perfused 
rat heart (Baydoun et al., 1989; Thompson et al., 1992). 
One possibility is that the renal metabolic activity of 
neutral endopeptidase 24.11 (enkephalinase) 
(Vijayaraghavan et al., 1990; Yamaguchi et al., 1992) and 
a distinct endothelin degradation enzyme (Deng et al., 
1992) may provide an efficient mechanism for the 
biological modification of ETs and the reversal of their 
vasoconstrictor effects (see Kimura et al., 1988).
In summary, ETs acted as equipotent vasoconstrictors in 
the isolated perfused rat kidney and the peak 
vasoconstrictor effects to lower doses of ET-1 were 
significantly sensitive to BQ123 (1/xM) . 30pmoles ET-1 and 
ET—2 displayed a prolonged recovery from peak 
vasoconstriction relative to 30pmoles ET-3 and this 
disparity could be shown for ET-1 to be dependent on an 
action at ET^ receptors. Overall, the findings generally 
support the notion that renal vasoconstriction to ETs is 
subserved by a mixed population of ET^ and ETs-like 
receptors.
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4.3. Vasoconstrictor reactivity in the isolated perfused
rat kidney after renal ischaemia and reperfusion in vivo
This study provides no evidence that renal vascular 
resistance is enhanced in vitro after 30min ischaemia or 
30min ischaemia and 15min reperfusion in vivo. This is in 
contrast to reports by Arendshorst et al. (1975), Clozel 
et al. (1991) and Paller et al. (1984) in vivo and 
Lieberthal et al. (1989) in vitro suggesting a 
postischaemic renal vasoconstriction in the rat kidney. 
The present discrepancy with these findings may be 
explained by the more severe lengths of occlusive renal 
ischaemia employed in these studies (45 or 60min). 
However, the study of Lieberthal et al. (1989) in the 
isolated rat kidney perfused with erythrocyte-rich salt 
solution employed a similar ischaemic (nonperfusion) time 
of 25 min. The present findings are in agreement with 
those of Linas et al. (1988) who demonstrated no change 
in renal vascular resistance in vitro after 20 min 
occlusive renal ischaemia in vivo in the rat. The above 
observations are however consistent with postocclusive 
renal vasoconstriction being an occlusive time-dependent 
phenomenon.
Although the apparent depression of vasoconstriction to 
noradrenaline after 30min ischaemia in vivo did not 
attain statistical significance, the potency of 
noradrenaline displayed a significant recovery with time
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in vitro. In contrast, no such shift in potency to 
noradrenaline was observed in kidneys subjected to 30min 
ischaemia and 15min reperfusion in vivo. The transient 
aberration of vasoconstrictor reactivity to noradrenaline 
is evocative of a stunning effect of reversible ischaemia 
on the renal microvasculature (see Bolli et al., 1988). 
These findings would seem to be specific for 
noradrenaline insomuch as no shift in potency to 5- 
hydroxytryptamine was observed over a similar perfusion 
period in vitro after 30min renal ischaemia in vivo. In 
addition, non-specific vasoconstrictor reactivity to KC1 
was not significantly altered in the ischaemic group. A 
depression in vasoconstriction to noradrenalnie has been 
noted by Kelleher et al. (1984) in the rat kidney during 
the recovery phase after noradrenaline-induced acute 
renal failure in vivo while Conger et al. (1991) have 
shown that vasoconstriction to noradrenaline is lost 
altogether after 75min ischaemia in the rat in vivo. This 
suggests that incremental periods of renal ischaemia in 
vivo may give rise to a graded loss of renal 
vasoconstrictor reactivity to noradrenaline. Indeed, 
Clozel et al. (1991) have reported a predominant renal 
vasodilator effect of noradrenaline in vivo after 45min 
renal ischaemia in the rat. There is some evidence to 
suggest that the apparent loss in vasoconstrictor 
reactivity to noradrenaline after ischaemia may involve a 
defect of the <*2-adrenoceptor (McGillivray-Anderson et 
al., 1991).
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Renal vasoconstriction to ET-1 and ET-3 in vitro was 
unaffected by 30min renal ischaemia in vivo. This is in 
good agreement with a study by Clozel et al. (1991) 
showing that renal vasoconstrictor responses to ET-1 in 
the rat in vivo were relatively well preserved after 
45min occlusive renal ischaemia. However, Clozel et al. 
(1991) also showed that vasoconstrictor reactivity to 
noradrenaline was abolished at this time. This was argued 
to favour a potential role for ET-1 in the observed 
postischaemic vasoconstriction in this study. An effect 
at the level of glomerular ET receptors accounting for 
the intact vascular reactivity to ET-1 after ischameia, 
would seem unlikely given the report by Wilkes et al.
(1991) that neither the density nor affinity of these 
receptor sites change after up to 60min occlusive renal 
ischaemia in the rat. The present study would suggest 
that such marked differential changes in vasoconstrictor 
reactivity to noradrenaline and ET-1, together with a 
change in postocclusive renal vascular resistance either 
do not occur or are not sustained following a renal 
ischaemic time of 30 min in vivo. However, this period of 
reversible ischaemia may nevertheless be associated with 
temporary defects in renal vasoconstrictor reactivity, at 
least to noradrenaline.
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4.4. Assessment of MPO activity in rat renal tissue after 
ischaemia/reperfusion in vivo: effects of antibodies 
against adhesion molecules used by PMNs
The present findings agree with those of Suzuki et al. 
(1983) that a TMB assay can provide a viable, safe 
alternative to the established o-dianisidine assay of 
MPO. A corollary of the enhanced sensitivity of the 
described TMB assay of MPO is that the threshold of 
detection is lowered. This theoretically provides for the 
assessment of early tissue PMN infiltration during 
reperfusion after ischaemia which might be overlooked 
using a less sensitive o-dianisidine assay (see Augustin 
& Lutz, 1991; Bird et al., 1988).
The masking of exogenous horseradish peroxidase activity 
by rat renal supernate indicates the presence of rat 
renal tissue factors that interfere with the peroxidase 
assay. Hillegas et al. (1990) have suggested that such 
factors may include conjugates of kidney-derived protein 
and the detergent HTAB, used to solubilise MPO. The level 
of inhibition (91%) exhibited by rat renal tissue 
assessed by the recovery of added horseradish peroxidase 
activity, was comparable to that reported by Schierwagen 
et al. (1990) (8 8%) measuring the recovery of exogenous 
human MPO activity in the rabbit kidney. However, in 
contrast to the findings of Schierwagen et al. (1990) in 
the rabbit kidney, the rat renal inhibition of exogenous
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peroxidase activity was not abolished by heat 
inactivation alone. In fact, the level of rat renal
inhibition remained significantly high at 49% after the
rat renal supernate had been incubated at 60°C for 2h.
The discrepancy between studies suggests the existence of 
both heat labile and heat stable interfering factors in 
rat renal tissue. The observation that rat renal 
inhibition was effectively abolished by the provision of 
excess peroxide to heat-inactivated rat renal supernate 
implies that the proposed heat stable factors are 
peroxide consuming systems. A conceivable role for such 
systems was postulated by Schierwagen et al. (1990). It 
is unlikely that the systems are themselves peroxidatic 
since no activity was detected in the renal supernate of 
non-ischaemic rat kidneys per se. Hence, tissue catalatic 
activity may be responsible. However, one prime 
candidate, the heat stable enzyme catalase, can probably 
be excluded since DMSO at 10% (v/v), which was present in 
all TMB assays, has been reported to abolish catalase 
activity in vitro (Rammler, 1967). Schierwagen et al.
(1990) reports no significant loss of human MPO activity 
after incubation at 60°C for 2h. The present 
determination of MPO from rat PMNs undergoing the same 
treatment similarly attests the heat stability of rat 
MPO.
The applicability of procedures designed to optimise the 
recovery of exogenous peroxidase activity from renal
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supernate in vitro, was demonstrated by the delineation 
of a time course for renal PMN accumulation using MPO as 
a biochemical marker after renal ischaemia/reperfusion in 
vivo. As further verification, no MPO activity could be 
detected in ischaemic/reperfused kidneys when the level 
of renal inhibition of added peroxidase activity was 91%. 
This emphasises the importance of assessing and 
overcoming the renal suppression of peroxidase activity 
before attempting ischaemia/reperfusion studies of renal 
PMN accumulation using MPO as a biochemical marker. 
Interestingly, Willinger et al. (1992) have 
histologically demonstrated PMN accumulation 
predominantly at intraglomerular, outer medullary and 
cortical peritubular sites in the rat kidney after 45min 
ischaemia and 2h reperfusion in vivo.
The conservative dose of MoAbs used in the present study 
(40/ug/kg i.v. total) was selected entirely on economic 
grounds. A preferred approach is to first examine the 
blocking efficacy of anti-adhesion molecules in in vitro 
models of PMN endothelial adherence such as those 
described by Argenbright et al. (1991) and Polhman et al.
(1986), and then to select a dose accordingly for in vivo 
use that would provide a similar concentration and 
presumably a similar blocking activity in vivo.
In the present study, the efficacy of MoAbs against ICAM- 
1 and CD18 of B2_integrins to block renal PMN
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accumulation after ischaemia/reperfusion, would suggest 
the involvement of these adhesion molecules in vivo. This 
would agree with previous studies in vitro indicating the 
importance of ICAM-1 and CD18 to PMN-endothelial cell 
adhesion (Argenbright et al., 1991; Pohlman et al.,
1986). However, the present results must be qualified by 
the findings that the isotype-matched control murine 
antibody, IgG^ in addition to an unrelated murine 
antibody, IgG2a/ reproduced this blockade of renal PMN 
accumulation.
One possibility worth investigating is that murine 
antibodies may reduce the circulating level of PMNs. It 
is conceivable that endogenous rat anti-murine isotype 
antibodies could form immune complexes with exogenous 
murine antibodies and thereby precipitate PMN priming or 
activation, possibly via complement activation. This 
could lead to neutropaenia due to reduced PMN 
deformability and the subsequent sequestration of PMNs in 
the pulmonary vascular bed (MacGregor, 1977; Worthen et 
al., 1989; Jagels & Hugli, 1992).
There was no evidence that exogenous horseradish 
peroxidase activity was inhibited by renal supernate 
exposed to the isotype-matched control murine antibody, 
IgG^. This indicates that murine antibodies do not 
directly affect tissue MPO activity in vitro. Taken 
overall, this suggests that murine MoAbs against rat
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adhesion molecules may be capable of depressing 
ischaemic/reperfused renal PMN accumulation at least in 
part by virtue of a non-specific action in vivo. FACS 
analysis which showed the selective binding of anti-CD18 
MoAb to rat blood PMNs, implies that a common, non­
specific action of murine antibodies at the level of the 
PMN membrane can be excluded. However, non-specific 
binding by other cell types such as endothelial cells 
cannot be discounted. The level of PMN accumulation in 
ischaemic/reperfused kidneys exposed to the vehicle (0.9% 
saline) alone was not significantly reduced, indicating 
that effects were related to antibody interventions.
The FACS data is consistent with the surface expression 
of CD18, but not ICAM-1, by PMNs. This could be further 
verified by performing a FACS anaysis on activated PMNs 
which are known to display an upregulated surface 
expression of CD18 (Albelda & Buck, 1990). In this case, 
the density of anti-CD18 MoAb binding would be expected 
to be enhanced.
The gain in wet weight of ischaemic/reperfused kidneys 
indicates oedema formation. This occurred in the presence 
and absence of demonstrable ischaemic/reperfused renal 
PMN accumulation. This suggests a largely PMN-independent 
rise in renal microvascular permeability in this model of 
renal ischaemia/reperfusion (Wedmore and Williams, 1981; 
Williams et al., 1990). Oedema-promoting factors linked
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with coagulation (Gerdin and Saldeen, 1978) may be 
excluded since animals were heparinised. Roles for local 
autocoids and/or vascular permeability factor (Collins et 
al., 1993) are conceivable. Alternatively, the integrity 
of the endothelial barrier may have been irreversibly 
damaged by ischaemia/reperfusion.
In summary, it has been found that a TMB assay provides a 
more sensitive photometric assessment of rat PMN-derived 
MPO than an established o-dianisidine assay. It was also 
determined that rat renal tissue factors which interfere 
with the assessment of rat renal tissue peroxidase 
activity could be surmounted by a combination of heat 
inactivation and the provision of excess assay H2O2 .
Renal PMN accumulation after ischaemia/reperfusion in 
vivo using MPO as a biochemical marker in a sensitive TMB 
assay, was subsequently demonstrated. Finally, the 
available evidence suggests that murine MoAbs against rat 
adhesion molecules may be effective in reducing renal PMN 
accumulation after ischaemia/reperfusion in vivo at least 
in part in a non-specific manner.
4.5. Conclusions
Histamine is not an EDRF(NO)-dependent vasodilator in the 
isolated perfused rat kidney. Histamine would therefore 
not be a suitable agent in an assessment of agonist-
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elicited renal EDRF(NO) function after 
ischaemia/reperfusion in the rat. The predominant 
receptors mediating renal vasodilation to histamine in 
the rat were determined to be H2 receptors. 
Vasoconstriction to endothelins in the isolated perfused 
rat kidney is mediated by a mixed population of ET^ and 
non-ET^, possibly ETg receptors. The ET^ receptor plays a 
role in prolonging the duration of vasoconstriction to 
ET-1 (and probably ET-2). Basal renal vascular resistance 
and vasoconstrictor reactivity to ET-1, ET-3, 
noradrenaline, 5-hydroxytryptamine and KC1 is not grossly 
affected in vitro following 30min ischaemia with or 
without 15min reperfusion in vivo. However, this period 
of ischaemia in vivo is sufficient to reversibly depress 
the renal vasoconstrictor potency of noradrenaline in 
vitro. Finally, rat renal tissue is capable of 
suppressing peroxidase activity. This suppression is 
surmountable by a combination of heat inactivation of the 
renal tissue and the provision of a suitably high level 
of peroxide in the assay mixture. Myeloperoxidase, a 
biochemical marker for polymorphonucleocyte accumulation, 
is detectable in rat kidneys after ischaemia/reperfusion 
in vivo. The earliest observed renal PMN accumulation 
occurred after 45min ischaemia and lh reperfusion. Murine 
monoclonal antibodies against rat adhesion molecules 
ICAM-1 and CD18, may be able to reduce renal PMN 
accumulation after ischaemia/reperfusion in a non­
specific manner in the rat.
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